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Abstract
One of the most consistent findings in schizophrenia is the dysfunction of specific subsets
of GABAergic interneurons in distributed brain regions including the prefrontal cortex
and cerebellum. Analyses of post-mortem tissue from cerebellar hemispheres from 13
schizophrenic patients and 13 matched controls by quantitative real-time PCR (qRTPCR) revealed that the mRNA levels of both the 67 kDa and 65 kDa isoforms of glutamic
acid decarboxylase (GAD67 and GAD65) are decreased. Additionally, the presynaptic
GABA transporter GAT-1 and the Golgi cell specific neuromodulator metabotropic
glutamate receptor 2 (mGluR2) were decreased in the schizophrenic group. Postsynaptic
upregulation of GABAA-α6 and δ along with downregulation of neuronal nitric oxide
synthase (nNOS), a negative modulator of GABA release, were also seen, suggesting a
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compensatory mechanism to counteract deficits in GABAergic transmission. In addition
to GABAergic alterations in schizophrenia, N-methyl-D-aspartate (NMDA) receptor
dysfunction has been proposed. To investigate this possibility, we measured NMDA
receptor subunit mRNAs in the same samples and found that the NR2B subunit showed a
near-significant decrease (p=0.0681) in the patients. In contrast, the kainic acid receptor
subunits GluR6 and KA2 were upregulated in the granule cell layer. In an effort to
understand the mechanisms for these gene expression changes, we examined adult rats
chronically exposed to NMDA receptor antagonist phencyclidine (PCP, 2.58 mg/kg/day,
i.p.), which elicits schizophrenia-like symptoms in both humans and animal models.
Analyses of PCP-treated rat cerebellar hemispheres demonstrated similar decreases in all
GABAergic marker mRNAs as seen in patients, as well as a decrease in Golgi cell
GAD67 as shown by quantitative in situ hybridization (qISH). Additionally, decreases in
both NR2B and NR2D transcripts, which are present in Golgi cells and colocalize extrasynaptically, were seen. Since low doses of PCP preferentially block NMDA receptors in
GABAergic interneurons, chronic PCP administration could preferentially affect Golgi
cells in the cerebellum.

Deficits in these GABAergic interneurons may lead to

disinhibited firing of cerebellar granule cells, as suggested by our previous studies of
increased activity-dependent gene expression in these neurons. In conclusion, our results
support the notion that GABA deficits are key elements in the pathophysiology of
schizophrenia.
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Chapter 1
Introduction

1.1 Schizophrenia
Schizophrenia is a complex and devastating neuropsychiatric disorder affecting
approximately 1% of the world’s population. An estimated $58 million is spent annually
dealing with the direct and indirect consequences of schizophrenia in the United States
alone (Uhl and Grow, 2004).

Both patients and their families are affected by the

damaging constellation of symptoms caused by the disease.

Schizophrenia is

characterized by positive (hallucinations, delusions, thought disorders), negative (flat
affect, alogia, avolition) and cognitive symptoms (impairments in learning and specific
areas of memory, i.e. working memory) (American Psychiatric Association, 2000; Lewis
and Lieberman, 2000). These symptoms tend to manifest during late adolescence to the
mid-twenties. They may be overwhelming and may contribute to suicide committed by
10% of schizophrenic patients.

Both genetic and environmental factors contribute to the complex pathophysiology
underlying schizophrenia. Approximately 50% of monozygotic twins with schizophrenia
will have an affected twin and approximately 17% of dizygotic twins and first-degree
relatives are also affected (Austin, 2005). Genes such as neuregulin (NRG1), dysbindin,
D-amino acid oxidase (DAAO), G72, catechol-o-methyl transferase (COMT), regulator
of G protein signaling 4 (RSG4), and disrupted in schizophrenia 1 (DISC1) have been
identified as susceptibility genes in schizophrenia (Rapoport et al., 2005; Duan et al.,
2007). These genes confer a risk, but seemingly need environmental insults to trigger
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disease onset. Environmental factors may include a range of aspects from prenatal stress
to viral infection in utero, but are more correlative than predictive (Austin, 2005).
Typically, patients start to manifest changes in behavior during the prodromal phase,
before their first psychotic episode. After this first-episode, subtle structural changes in
the brain are seen, such as increased ventricular size and reduction in cortical grey matter
and related areas (Potkin et al., 2002). This is due primarily to an overall reduction in
cell size and synaptic connectivity, not as a reduction in neuronal numbers (Lewis and
Lieberman, 2000).

Classical treatments for schizophrenia involve the administration of typical or atypical
antipsychotics. Typical antipsychotics, such as haloperidol and chlorpromazine, bind
primarily to dopamine (DA) D2 receptors to antagonize receptor effects.

Atypical

antipsychotics, such as clozapine and risperidone, bind to a broader range of receptors
including D4, 5-HT2A and noradrenergic receptors among others (Kapur and Remington,
2001). While typical antipsychotics are effective at relieving the positive symptoms
mediated by D2 receptor blockade (Snyder, 2006), they are not effective in ameliorating
the negative and cognitive symptoms (Lieberman et al., 2005; Ross et al., 2006). These
aspects of schizophrenia are better indicators of the severity of the disease than are the
positive symptoms and they show gradual deterioration as the disease progresses.
Additionally, typical and atypical antipsychotics may produce unwanted side effects,
including extrapyramidal side effects, prolactin increase, and weight gain to name a few
(Lewis and Lieberman, 2000; Kapur and Remington, 2001; Freedman, 2005). While
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these medications manage positive symptomology effectively, further research is needed
in order to effectively treat the negative and cognitive symptoms.

1.2 Role of Glutamate and NMDA Receptors in Schizophrenia
While dopaminergic dysfunction in schizophrenia is widely accepted, a growing body of
evidence suggests the involvement of glutamate and γ-aminobutyric acid (GABA)
alterations in this illness (Akbarian and Huang, 2006; Kristiansen et al., 2007). The
glutamate hypothesis of schizophrenia states that symptoms are related to hypofunction
of N-methyl-D-aspartate (NMDA) receptors. Glutamate activates ionotropic NMDA
receptors allowing for the influx of Na+ and Ca2+ leading to excitation and cellular
signaling. These channels have been implicated in processes encompassing development,
long-term potentiation (LTP), and excitotoxicity (Llansola et al., 2005). Each channel
consists of an obligatory NR1 subunit and co-assembles with any of the NR2A-D
subunits, each conferring upon the channel distinct electrophysiological and biochemical
properties. Channels containing NR2A and NR2B are thought to be high conductance
channels while NR2C and NR2D containing channels are low conductance channels
(Misra et al., 2000). NR2C and NR2D are more prone to NMDA receptor antagonism
due to less Mg2+ block and longer open channel time than either NR2A or NR2B
(Monyer et al., 1994; Grunze et al., 1996). These subunits localize more to interneurons
that express γ-amino butyric acid (GABA) in the hippocampus (Monyer et al., 1994).
GABAergic interneurons in other brain regions express different combinations of NR2
subunits in NMDA channels, such as seen in Golgi cells in the cerebellum, which express
the NR2B and NR2D subunits (Misra et al., 2000; Brickley et al., 2003). Furthermore,
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the NR2B subunit is more prone to antagonism than is the NR2A subunit as seen in
pharmacological studies of prepulse inhibition and locomotor activity in rats (Chaperon
et al., 2003). Decreased expression of NMDA receptor components or selective block by
NMDA receptor antagonists, such as MK-801 or phencyclidine (PCP), will alter the
functional properties of cells containing NMDA receptors. These alterations may lead to
downstream gene expression alterations, diminished LTP, or aberrant development, all
important in the pathophysiology underlying schizophrenia.

NMDA receptor dysfunction has been characterized in different brain regions in
schizophrenic patients (Kristiansen et al., 2007). The levels of different receptor subunits
were shown to be altered in the prefrontal cortex (Akbarian et al., 1996b; Dracheva et al.,
2001) and limbic areas (Kristiansen et al., 2006; McCullumsmith et al., 2007), and SPET
studies have demonstrated decreased NMDA receptor binding in the hippocampus in
schizophrenics (Pilowsky et al., 2006). Studies of NMDA receptor antagonists further
implicate hypofunction of these channels in schizophrenia (Coyle, 2006). Administration
of these agents elicits symptoms similar to that of schizophrenia in healthy adults, with
negative and cognitive symptoms as well as overt psychosis (Adler et al., 1999), and
exacerbation of symptoms in schizophrenic patients.

NMDA receptor dysfunction,

particularly on specific subsets of GABAergic interneurons, may be central to
schizophrenia (Lewis and Gonzalez-Burgos, 2000; Coyle, 2006).

NMDA receptor

antagonists have been shown to selectively block NMDA channels located on
GABAergic interneurons (Grunze et al., 1996; Rujescu et al., 2006; Homayoun and
Moghaddam, 2007).

These findings may be of great importance since GABAergic
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interneurons are known to be an essential component in modulating the synchronization
of neuronal activity necessary for highly demanding cognitive tasks (Traub et al., 1996).

1.3 Role of GABA in Schizophrenia
GABA is synthesized by the 65kDa and 67kDa forms of glutamic acid decarboxylase
(GAD65 and GAD67), each the product of different genes (Erlander et al., 1991). These
enzymes remove the carboxyl group from L-glutamate to produce GABA.

GAD65

protein is present in greater abundance in axon terminals while GAD67 localizes
preferentially to the soma. However, mRNA for both is localized to cell bodies of
GABA positive cells (Esclapez et al., 1994). Additionally, GAD67 expression is more
activity dependent than GAD65 as seen by increased levels in models of epilepsy (Sloviter
et al., 1996; Freichel et al., 2006). Once synthesized, GABA is released mainly by
interneurons throughout the brain. These interneurons modulate the activity by either
synchronizing and/or disabling excitatory cell signaling.

The presynaptic GABA

reuptake transporter (GAT-1) removes any remaining GABA from the synaptic cleft,
effectively ending GABAergic neurotransmission. Therefore GAD65, GAD67, and GAT1 are crucial to control GABA mediated transmission and overall brain function.

GABA dysfunction in certain subsets of GABAergic interneurons is one of the most
consistent findings in the study of schizophrenia (Woo et al., 2004; Lewis et al., 2005;
Torrey et al., 2005; Akbarian and Huang, 2006). Reductions in mRNA and protein levels
of GAD67 were reported in the prefrontal cortex (PFC) (Volk et al., 2000; Hashimoto et
al., 2003; Lewis et al., 2004), the hippocampus (Benes and Berretta, 2001; Heckers et al.,

5

2002), and the cerebellum (Guidotti et al., 2000; Fatemi et al., 2005). In addition to
decreased expression of GAD67, chandelier and basket interneurons in the PFC show
decreased mRNA levels for GAT-1 (Volk et al., 2001) and the calcium binding protein
parvalbumin (Lewis et al., 2001) (Figure 1.1).

Figure 1.1: Representation of prefrontal circuitry showing deficits in specific subsets of GABAergic
interneurons. Chandelier and basket cells in patients with schizophrenia show decreased mRNA levels of
GAD67, GAT-1, and parvalbumin as well as increased immunoreactivity in pyramidal GABAA-α2.
Reproduced from Lewis, et al., 2005.
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Postsynaptic changes such as increases in GABAA-α2 receptor density and GABAA
receptor radioligand binding in the PFC and anterior cingulate cortex were also observed
(Benes et al., 1992; Benes et al., 1996; Volk et al., 2002). Additionally, single nucleotide
polymorphisms in the promoter region of the GAD67 gene were shown to be associated
with reductions in grey matter in patients with childhood-onset schizophrenia (Addington
et al., 2005) and with decreased cognitive functioning in adult patients (Straub et al.,
2007). Considering the role of GABAergic interneurons in the modulation of excitatory
output, it can be hypothesized that dysfunction in these cells may mediate some of the
positive, negative, and cognitive (Spencer et al., 2004) symptoms seen in schizophrenia.

1.4 Cerebellar Contributions to Schizophrenia
Traditionally most of the research performed in the field of schizophrenia has focused on
brain regions directly implicated in the symptomology of the disease, mainly the
prefrontal cortex and limbic areas. However, Andreasen et al (1997) have implicated the
cerebellum as an affected region in schizophrenia through its connections in the corticocerebellar-thalamic-cortical circuit (CCTCC). Dysfunction in one area of this circuit will
affect all other areas of the circuit.

As a component of the CCTCC, the lateral

hemispheres of the cerebellum have been implicated in cognitive (posterior cerebellar
lobe) and emotional (cerebellar vermis) functioning (Schmahmann and Sherman, 1998).
Retroviral tracing and neuroimaging studies have shown connections between
cerebellum-prefrontal (Middleton and Strick, 2001) and cerebellar-parietal areas (Allen et
al., 2005).

These connections have major implications in cognitive dysfunction in

schizophrenia.

Intrinsic to these connections, a forward modeling system of the
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cerebellum has been proposed where information from the motor cortex or the PFC is
transferred to the cerebellum and the cerebellum acts as a predictor of the outcome for
both motor (anterior cerebellar lobe) and cognitive functioning. Connections to the
dorsolateral PFC (DLPFC) were shown to localize to the lateral hemispheres of the
cerebellum, particularly in crus I and crus II of lobule VII (Kelly and Strick, 2003;
Ramnani, 2006).

Therefore, lateral cerebellar hemisphere connections to higher

cognitive areas of the brain implicate the cerebellum in cognitive functioning and
subsequently in schizophrenia.

Clinically, patients exhibit cerebellar neurological signs (Ho et al., 2004), deficits in
eyeblink conditioning (Sears et al., 2000), and shortfalls in timing responses (Brown et
al., 2005). Neuroimaging studies have shown increases in blood flow and in glucose
consumption in the cerebellum of schizophrenic patients relative to that of other brain
regions (Andreasen et al., 1997; Kim et al., 2000b; Potkin et al., 2002; Malaspina et al.,
2004). In accordance with increased cerebellar activity, our laboratory found that activity
dependent genes expressed by granule cells, GAP-43 and BDNF, are upregulated in the
cerebellum (Paz et al., 2006).

Additional molecular studies have shown decreased

expression of the development markers reelin and semaphorin 3A as well as GABA
synthesizing enzymes GAD65 and GAD67 (Guidotti et al., 2000; Eastwood et al., 2003;
Fatemi et al., 2005). This is interesting considering the fact that GABA deficits in Golgi
interneurons of the cerebellum may lead to aberrant cerebellar output due to disinhibition
of granule cell firing. This in turn could account for the increases seen in blood flow,
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glucose utilization, and the increased expression of activity dependent genes. These
changes ultimately impact cerebellar contributions to cognitive (and motor) functioning.

Apart from the cognitive aspects of the cerebellum, other factors make this region
particularly interesting for the study of schizophrenia.

The local circuitry of the

cerebellum with the granule cell-Golgi cell interaction can be compared morphologically
and physiologically with the pyramidal cell-chandelier cell interaction in the PFC
implicated in schizophrenia (Lewis et al., 2005). The excitatory granule cell of the
cerebellum receives input from pontine mossy fibers. Activation by mossy fibers excites
granule cells and causes them to
activate Purkinje cells, which are the
sole output of the cerebellum. This
interaction is modulated in a phasic
manner

by

Golgi

cells,

which

function in a negative feedback loop
with granule cells (Watanabe et al.,
1998; Hirano et al., 2002) (Figure
1.2), in a structural and functional
unit

named

the

cerebellar

glomerulus. GABA function in the
glomerulus is regulated by various
factors,

including

GABAA

receptors,

postsynaptic
presynaptic

Figure 1.2: Golgi cell circuit and the cerebellar
glomerulus (green). Granule cells (GrC; blue) are
excited by pontine mossy fibers (MF; yellow). GrC
parallel fibers (PF) synapse on Purkinje (PC; not
shown), basket (BC; not shown), stellate (SC; not
shown), and Golgi cells (GoC; purple). The GoC
provide inhibitory feedback to the GrC for synchronized
activity . Reproduced from De Schutter, 2002.
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metabotropic glutamate receptors (Geurts et al., 2003), pre- and post-synaptic kainate
receptors (Fiszman et al., 2007; Mathew et al., 2008), and retrograde nitric oxide (NO)
synthesized by neuronal nitric oxide synthase (nNOS) (Wall, 2003).

Golgi cells normally impart GABAergic tone on the granule cell (Hamann et al., 2002;
Geurts et al., 2003; Rossi et al., 2003; Chadderton et al., 2004) through intrinsic
autorhythmic firing (Forti et al., 2006). Therefore, dysfunctions of Golgi cells in this
circuit leads to disinhibited firing of the granule cells, potentially accounting for the
increased activity and the subsequent changes seen by neuroimaging (Andreasen et al.,
1997; Kim et al., 2000b; Potkin et al., 2002; Malaspina et al., 2004) and molecular
studies (Paz et al., 2006). Golgi cells express GABA synthesizing enzymes GAD65 and
GAD67 as well as GAT-1 (Takayama and Inoue, 2005) and the NMDA receptor subunits
NR2B and NR2D (Misra et al., 2000; Brickley et al., 2003).

These subunits are

preferentially targeted by NMDA receptor antagonists such as PCP (Grunze et al., 1996;
Rujescu et al., 2006).

Altogether these data implicate Golgi cells as the affected

interneuron in the cerebellar GABAergic dysfunction seen in schizophrenia.

In addition to Golgi and Purkinje cells, basket and stellate interneurons are the other
major GABAergic cells in the cerebellum. Basket cells and stellate cells both provide
feedforward inhibitory modulation to Purkinje cells.

Basket cells synapse on the

proximal dendrite, soma, and axon of the Purkinje cell while stellate cells synapse on the
distal dendritic tree (Takayama and Inoue, 2005). Both cell types help the Purkinje cell,
which also receives input via inferior olive climbing fibers, integrate granule cell
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information and modulate Purkinje cell output (Midtgaard et al., 1993). Basket and
stellate cells both express GAT-1 (Takayama and Inoue, 2005) while Purkinje cells only
express GAT-1 transiently during development (Yan and Ribak, 1998). While Golgi
cells influence Purkinje cell function by modulating granule cells, decreased basket
and/or stellate cells activity directly contributes to unregulated Purkinje cell firing. This
unregulated activity of Purkinje cells mediated by GABAergic interneuron dysfunction
may also contribute to cerebellar pathology in schizophrenia.

Of further interest, the lateral hemispheres of the cerebellum do not contain any direct
dopaminergic input (Schweighofer and Doya, 2003), making this system more purely
glutamate/GABA than is seen in other brain regions with dopaminergic input, such as the
PFC. Therefore, studying the cerebellum could be useful in determining the direct
pathophysiological consequences of schizophrenia with minimal effects from medication.
In addition, the cerebellum has intrinsic neuroprotective pathways mediated by low level
basal NMDA receptor activation leading to BDNF release and subsequent TrkB
activation (Jiang et al., 2003; Wu et al., 2005; Xifro et al., 2005). Native cerebellar
neuroprotection may be accountable for the increase in blood flow and glucose
consumption seen in neuroimaging studies and in increased expression of activity
dependent genes. Taken as a whole these findings indicate the cerebellum participates in
the pathophysiology of schizophrenia.
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1.5 Medication Effects on Gene Expression
Antipsychotic medication by itself can differentially affect gene expression in distributed
brain regions. Typical antipsychotics include such drugs as chlorpromazine, thioridazine,
and haloperidol, the prototypical typical antipsychotic. Haloperidol is thought to increase
GAD67 mRNA levels through signaling mechanisms mediated through blockade of D2
receptors (Lipska et al., 2003). Increased levels of GAD67 and GAT-1 were reported in
the medial frontal cortex, striatum, and nucleus accumbens in rats (Laprade and
Soghomonian, 1995; Lipska et al., 2003; Zink et al., 2004a; Zink et al., 2004b).
Conversely, Volk et al (2000, 2001) report no change in expression of these levels in
non-human primates in the PFC. Furthermore, magnetic resonance spectroscopy (MRS)
studies found that typical antipsychotics do not alter the levels of glutamate, glutamine,
or N-acetylaspartate (NAA) (Bustillo et al., 2006), which is considered a putative marker
of cellular integrity.

However, medication effects have not been studied in the

cerebellum and merit further consideration.

Atypical antipsychotics have been shown to upregulate the GABAergic markers GAD67
and GAT-1 in prefrontal and limbic areas through unknown mechanisms (Zink et al.,
2004a; Zink et al., 2004b). Also, anti-apoptotic genes such as Bcl-2 were shown to be
upregulated by atypical antipsychotics, seemingly imparting neuroprotection (Bai et al.,
2004). These same drugs also showed alterations in NMDA receptor subunit expression
(Hanaoka et al., 2003) and reversed the functional hyperactivity produced by NMDA
receptor antagonists such as PCP (Ninan et al., 2003). In light of these data, medication
effects seem to be significant contributors to the overall cellular and molecular changes
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observed in patients. Since the vast majority of patients are currently on neuroleptics
these effects need to be researched for understanding their effects in treating
schizophrenia.

1.6 Phencyclidine
Phencyclidine (PCP) is a
non-competitive
receptor

antagonist

NMDA
(for

review see Morris et al.,
2005).

Initially used as a

surgical anesthetic, its use
was discontinued because it
caused

symptoms

similar

to

very

schizophrenia

(Jentsch and Roth, 1999;

Figure 1.3: An NMDA channel illustrating the binding sites for
neurotransmitters, binding factors, Mg2+, and PCP. PCP is a noncompetitive antagonist. Reproduced from Feldman and Quenzer,
1984.

Morris et al., 2005; Hajszan
et al., 2006), but is still continued to be used illicitly known on the street as “angel dust”
or “hog”. Like MK-801, PCP binds in the pore of open NMDA channels near the ion
selectivity filter (Ferrer-Montiel et al., 1998), blocking cation flow though the channel
(Figure 1.3). It acts in a dose dependent manner (Morris et al., 2005) and selectively
blocks NMDA channels located on GABAergic interneurons (Grunze et al., 1996;
Homayoun and Moghaddam, 2007). Thus, PCP disrupts GABAergic interneurons from
modulating the activity of glutamatergic cells with which they synapse leading to
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increased glutamate release (Jackson et al., 2004).

This, in turn, could lead to

downstream excitotoxic effects, such as neuronal damage and/or cell death. Because of
the selective effect of PCP on GABAergic interneurons, areas more susceptible to
excitotoxic damage, such as the PFC, are more vulnerable to the effects of PCP
administration whereas areas such as the cerebellum, with its neuroprotective
mechanisms, are not (Jiang et al., 2003; Wu et al., 2005; Xifro et al., 2005). Therefore,
NMDA receptor hypofunction may be accountable for the neuroimaging findings of
hypofrontality (Andreasen et al., 1992; Wolkin et al., 1992). Animal models utilizing
NMDA receptor blockade through PCP may be an effective tool in studying the
pathophysiological processes cardinal to schizophrenia.

1.7 Chronic Low-Dose PCP Administration in Rats
Animal models exploiting the GABA/glutamate system have proven useful in studying
the underlying pathophysiology of schizophrenia. Models include picrotoxin induced
antagonism of GABAA receptors in rats (Berretta et al., 2001), genetic knockdown of
NMDA NR1 subunit in mice (Mohn et al., 1999), and NMDA receptor blockade by
NMDA receptor antagonists, such as PCP and MK-801, in both rodents and non-human
primates (Jentsch et al., 1997b; Jentsch et al., 1997a; Jentsch and Roth, 1999; Cochran et
al., 2003; Morris et al., 2005; Rujescu et al., 2006). All these models affect the same
system in different manners, but only the PCP model has reproduced GABAergic and
NMDA receptor changes seen in schizophrenic patients (Cochran et al., 2003; Lindahl
and Keifer, 2004).
schizophrenia.

PCP elicits in humans many of the symptoms inherent to

Studies are now being conducted focusing on administering the
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compound to rodents and primates to simulate a schizophrenic phenotype in the animals.
Acute and chronic dosing regimens show differential and often opposing effects in
rodents (Jentsch and Roth, 1999). Immediately after administration of PCP, neurons of
the PFC show an initial paradoxical excitation as seen by activation of early immediate
genes (Gao et al., 1998). This is followed by a period of cortical depression as described
in glucose utilization studies (Gao et al., 1993), presumably because glutamate is
depleted.

Acute PCP also produces schizophrenia-like symptoms including social

withdrawal (Sams-Dodd, 1997), impaired sensory motor gating (Mansbach and Geyer,
1989) and cognitive dysfunction (Jentsch et al., 1997b; Jentsch et al., 1997a). Chronic
low dose administration of PCP in rodents showed decreased metabolic activity in the
medial frontal cortex PFC, auditory cortex, hippocampus, and reticular nucleus of the
thalamus (Cochran et al., 2003), all regions affected in schizophrenia.

Along with

decreased metabolic function, decreased parvalbumin expression was also seen in the
PFC and reticular nucleus of the thalamus (Cochran et al., 2003). This mirrors the
chandelier and basket cell dysfunction seen in the prefrontal cortex of schizophrenic
patients (Hashimoto et al., 2003). Additionally, levels of NAA and its metabolite nacetylaspartylglutamate (NAAG) are also altered with chronic PCP similar to that seen in
schizophrenic patients (Reynolds et al., 2005; Bustillo et al., 2006). Taken together, the
data suggest that the model Cochran et al (2003) proposed of chronic intermittent
exposure to low levels of PCP is the most functionally and neurochemically relevant
animal model based on GABAergic interneuron dysfunction.
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1.8 Goals of this Study
GABAergic dysfunction and NMDA receptor hypofunction have been characterized in
schizophrenia in multiple brain regions (Torrey et al., 2005; Akbarian and Huang, 2006;
Kristiansen et al., 2007). However, these changes have not been as extensively studied in
the cerebellum. This study is designed to assess the presence and localization of GABA
signaling deficits in the cerebellum of patients with schizophrenia. Experiments in this
study sought to test the overall hypothesis that dysfunction of certain GABAergic
interneurons, specifically Golgi cells, underlies the pathophysiology of schizophrenia in
the cerebellum.

Initial experiments involved characterizing both the transcript levels of GABAergic
markers, NMDA receptor subunits, and neuromodulators in the lateral cerebellar
hemisphere of post-mortem tissue from patients with schizophrenia versus pair matched
controls using qRT-PCR analysis. Given the fact that other brain regions showed deficits
in GABAergic gene expression, these studies examined the hypothesis that GABA deficits
exist in the cerebellum of patients. Gene expression effects of typical and atypical
medication were evaluated by examining mRNA levels of the same transcripts in rats
treated with either haloperidol or clozapine.

Subsequent experiments compared gene expression in the cerebellum of a proposed
animal model of chronic intermittent low-dose PCP to that seen in patients. Considering
that PCP elicits many of the symptoms seen in patients with schizophrenia in both
humans and animal models, these studies tested the hypothesis that chronic intermittent
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administration of low doses of PCP in rats will reproduce the gene expression changes
seen in the cerebellum of patients with schizophrenia.

qRT-PCR was also used to

examine this hypothesis.

Finally, we localized changes in the main GABA synthesizing GAD67 to specific
interneurons in the cerebellum of PCP treated rats. Since GABAergic interneurons are
preferentially affected by PCP administration and PCP rats reproduced the GABA
deficits seen in patients with schizophrenia, we tested the hypothesis that Golgi cells, the
interneurons responsible for negative feedback, are deficient in GAD67 expression. This
hypothesis was evaluated using quantitative in situ hybridization.

Overall, these studies support the hypothesis that specific subsets of GABAergic
interneurons are deficient in patients with schizophrenia. Additionally, these experiments
will also help validate the chronic low dose PCP treatment paradigm in rats as an animal
model for GABAergic dysfunction related to schizophrenia. Ultimately, this project will
provide important information to support (or disprove) the notion that the cerebellum is
an affected component in the brain of patients with schizophrenia.
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Chapter 2
Methods
2.1 Human Subjects
Cerebellar tissue from 13 patients with a diagnosis of schizophrenia according to DSM–
IV criteria and 13 sex-, age- and postmortem interval (PMI)-matched comparison
subjects was acquired from the Maryland Brain Collection (Table 2.1). All subjects were
male between 25 and 65 years of age at the time of death with a PMI lower than 24 hours.
None of the subjects had a history of alcohol abuse or dependence. No significant
differences were found between patients with schizophrenia and control subjects in mean
age (43.5+11 years vs. 40.9+8 years), PMI (12.1+5.1 hours vs. 16.5+5.4 hours) or RIN
(6.53+0.2 vs. 6.50+0.1). Six of the patients were receiving typical antipsychotics and
seven were receiving atypical antipsychotics at the time of death. Neither patients nor
control subjects were receiving medications for mood disorders. Tissue used in this study
originated from the lateral cerebellar hemisphere corresponding to crus I of lobule VIIA,
which was dissected at –20oC and frozen at –80oC until use.

2.2 Haloperidol Treated Rats
RNA from the cerebellum of haloperidol treated rats was acquired from a previous study
(Bustillo et al., 2006). Briefly adult male Sprague-Dawley rats (n=16) were injected i.m.
either

with

38

mg/kg/month

haloperidol-depo

(Novaplus),

corresponding

to

~1/mg/kg/day, or with sesame oil (vehicle). These rats were pair housed and kept on a
12:12 light:dark cycle. After a 7 day acclimation period the rats were injected once a
month for 6 months. The rats were anesthetized using isoflurane and decapitated one
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TABLE 2.1: Postmortem Characteristics of Schizophrenia and Comparison Subjects
Group

IDN

Gender

Race

Age (years)

Postmortem interval
(hours)

RIN

Treatment

Cause of Death

M
M
M
M
M
M
M
M
M
M
M
M
M

Black
Black
White
White
Black
Black
Black
White
White
White
White
White
Black

33
31
32
37
38
38
42
45
46
49
59
53
62

12
14
7
14
6
5
21
6
20
16
13
11
12

7.40
8.30
8.00
7.30
7.80
8.50
7.80
8.40
8.50
7.50
8.40
7.90
8.00

Olanzapine
Clozapine
Clozapine
Risperidone
Fluphenazine
Chlorpromazine
Perphenazine
Olanzapine
Olanzapine
Thioridazine
Haloperidol
Perphenazine
Olanzapine

Appendicitis
ASCVD
Suicide
Suicide
Asphyxia
Pneumonia
Tuberculosis
Suicide
ASCVD
Intoxication
Embolism
ASCVD
ASCVD

a

Schizophrenia subjects
1
42a
2
39*
3
7s
4
41
5
3s
6
11s
7
5s
8
18
9
31
10
5
11
36
12
1s
13
1
Comparison subjectsb
1
35
2
8s
3
12s
4
34*
5
4s
6
4*
7
40
8
12
9
10s
10
6s
11
17
12
21*
13
2s

M
Black
33
14
8.60
M. Obesity
M
Black
27
14
7.80
Asthma
M
White
31
16
7.80
Polytrauma
M
White
35
16
7.70
ASCVD
M
White
38
24
7.70
Asphyxia
M
Black
38
12
7.50
CMP
M
White
43
20
7.50
ASCVD
M
White
47
6
8.30
ASCVD
M
White
46
24
7.00
Arrhythmia
M
White
47
17
7.50
Arrhythmia
M
White
48
19
8.00
Sub-archn
M
White
49
10
7.30
ASCVD
M
White
50
22
7.80
ASCVD
a
Mean age was 43.5 years (range=31-62); mean postmortem interval was 12.1 hours (range=5-21); mean RIN was 7.98 (range=7.40-8.50).
b
Mean age was 40.9 years (range=31-50); mean postmortem interval was 16.5 hours (range=6-24); mean RIN was 7.73 (range=7.00-8.60).
1-13
Pairs matched according to age and PMI.
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month after the last injection. The cerebellum was removed intact, frozen on dry ice, and
stored at -80oC.

2.3 Clozapine Treated Rats
Adult male Long-Evans rats (n=20) were injected either with 10 mg/kg/day clozapine
(Novartis, Princeton, NJ) dissolved in 0.4% acetic acid in 0.9% saline, or with 0.4%
acetic acid in 0.9% saline i.p. for 21 days. This paradigm was modified from methods
described by (Bai et al., 2004), which suggested maximum D2 receptor occupancy for
clozapine. Eighteen hours following the last injection, the cerebellum of control and
clozapine treated rats was removed and the lateral hemispheres dissected and frozen at 80oC.

2.4 PCP Treated Rats
For quantitative real-time PCR (qRT-PCR) experiments, pair housed adult male LongEvans rats (n=20) were injected intraperitoneally with 2.58 mg/kg/day of either PCP
dissolved in saline or saline alone (Cochran et al., 2003). After an acclimation period of
7 days the rats were injected once a day for the first five days, then injected on days 8, 10,
12, 15, 17, 19, 22, 24, and 26. The rats were anesthetized using isoflurane and sacrificed
after a washout period of 72 hours. The lateral hemisphere of the cerebellum was
removed and frozen on dry ice. Samples were stored at -80oC.

For in situ hybridization and immunohistochemistry studies, a separate group of rats
(n=10) were injected as previously described. The cerebellum was removed and flash
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frozen in isopentane that was cooled at -40oC using methanol/dry ice. Samples were
stored at -80oC.

2.5 Sectioning of PCP Treated Rat Tissue
Frozen rat cerebellar tissue was cut to 10 µm thick sections on a cryostat. Each slide had
one coronal section from a PCP treated rat and its pair-housed saline control rat. A total
of five slides per rat pair were taken, each slide with one PCP and one saline control rat.
Slides were stored at -80oC.

2.6 Quantitative Real-Time PCR (qRT-PCR)
All experimental procedures and data analyses were performed blind to the diagnosis.
Human and rat tissue was homogenized using a Polytron homogenizer (Brinkmann
Instruments, Inc.; Westbury, NY) and total RNA was isolated using TriReagent (Sigma;
St. Louis, MO).

The integrity of samples was validated using a Bioanalyzer 2100

(Agilent Technologies; Santa Clara, CA). Samples were used for analysis only if RNA
integrity number (RIN) >7.0 for human samples and >8.0 for rat samples. cDNA was
synthesized from 4µg total RNA using M-MLV reverse transcriptase (Promega;
Madison, WI). qRT-PCR reactions were run on an Applied Biosystems 7000, 7300, or
7500 Fast quantitative Real-Time PCR machine. Gene expression levels in humans, PCP
treated rats, and neuroleptic-treated rats were examined using SYBR Green (Applied
Biosystems; Foster City, CA) with the exception of GABAA-α6 and GABAA-δ, which
were analyzed using TaqMan® Assays-on-Demand probes (Applied Biosystems), all
according to the manufacturer’s protocols.
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Exon spanning primer pairs (Operon;

Huntsville, AL) specific to GABAergic markers GABAA-β3, GAD67, GAD65,
Parvalbumin (human only), and GAT-1, NMDA receptor subunits NR1, NR2A, NR2B,
NR2C, and NR2D, and cerebellar neuromodulators GluR6, KA2, mGluR2, mGluR3, and
nNOS were designed with Primer Express 3.0 (Applied Biosystems) (Table 2.2). Genes
of interest were normalized by the housekeeping genes β-actin and cyclophilin.
Dissociation curves were examined for all SYBR® green primer pairs and validated
against housekeeping genes with a linear slope <|0.1|. Samples were run in triplicate in
three separate plates and compared to housekeeping gene on the same plate. The relative
levels of expression of each mRNA was corrected by β-actin and reconfirmed by
cyclophilin (Supplementary Figures A.4.1 – A.4.3) as previously described (Paz et al.,
2006) and the relative levels of transcript in patients vs. controls (human) or treatment vs.
vehicle (rat) were calculated using the 2-∆∆Ct method (Livak and Schmittgen, 2001).

2.7 qRT-PCR Data and Statistical Analysis
The averaged values per sample were entered into Prism 4.0 (GraphPad Software; San
Diego, CA) and analyzed using the Wilcoxon Signed Rank analysis for pair-matched
human subjects (see Appendix A.3 for unpaired data analyzed by t-tests) and t-tests for
rat samples.

Values were expressed as a ratio of schizophrenics/controls (S/C),

drug/vehicle (D/V), or PCP/Saline (P/S). SSPS 15.0 for Windows (SPSS Inc.; Chicago,
IL) was used for further analysis of human subjects, which included analyses of
covariance (ANCOVA) to determine the effect of age, PMI, and RIN on each gene’s
transcript expression and bivariate Spearman’s ρ correlation analysis to examine putative
gene-gene interactions. Any statistical
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TABLE 2.2: Human and Rat Primer Pairs for Quantitative Real-Time PCR
Amplicon
Size (bp)

Gene

Amplicon
Size (bp)

Human

Rat

b

SYBR® Green Primer Pairs
β-actin
242

5'-GGA CTT CGA GCA AGA GAT GG-3'
5'-AGC ACT GTG TTG GCG TAC AG-3'

120

5'-GAG GCC CCT CTG AAC CCT AA-3'
5'-ACC AGA GGC ATA CAG GGA CAA-3'

120

5'-GCC CTG AGG CAC TCT TCC A-3'
5'-TGT TGG CGT ACA GGT CTT TGC-3'

Cyclophilin A

225

5'-GCC GAG GAA AAC CGT GTA CTA TT-3'
5'-GTC ACC ACC CTG ACA CAT AAA CC-3'

GABAA-β3

120

5'-CCA CGA CAG CAG CAT GCA T-3'
5'-CGC CTC GCC AGT AAA ACT CA-3'

120

5'-GCT CGA GTT GCC CTA GGG ATT-3'
5'-CGA AGC AAC CCA TCA GGT ACA-3'

GAD65

226

5'-GCC TCC TAC CTC TTT CAG CA-3'
5'-TCC CAT CAA ACA CCA TCT CA-3'

120

5'-CGG AAC AGA CAG CGT GAT TCT-3'
5'-GCA CTC ACC AGG AAA GGA ACA-3'

GAD67

291

5'-TGG CAC GAC TGT TTA TGG AG-3'
5'-TAC TGC TTG TCT GGC TGG AA-3'

120

5'-CTG CCA TCC TGG TCA AGG AA-3'
5'-GAA TCG CCT TGT CCC CTG TA-3'

GAT-1

283

5'-TGC ATC TGG TGG AAA CTC TG-3'
5'-GCT GCT CAG GAC CAT TCT CT-3'

132

5'-GCC CTG GAC TGG CAT TCT T-3'
5'-AGC CCT CCA CGG TAC AGA ACT-3'

Parvalbumin

202

5'-CTA CCG ACT CCT TCG ACC AC-3'
5'-GCC ATC AGC ATC TTG GTT TC-3'

NR1

123

5'-CCA GGC GGA GAG ACA GAG AA-3'
5'-CTC CTT GCA TGT CCC ATC ACT-3'

128

5'-AAT GTG ACG GCT CTG CTG ATG-3'
5'-TAC CCA GAG CCC GTC ATG TT-3'

NR2A

125

5'-ATG GGA AAA GGT GGG CAA GT-3'
5'-CCT CCA GGG TGA CGA TGC T-3'

120

5'-GCC TCC GTC TGG GTG ATG AT-3'
5'-GGG AGC TTT CCC TTT GGC TAA-3'

NR2B

120

5'-TGG AGG AGG CAC CAT TTG TC-3'
5'-CCG GCT CCT CGT CTG TTT TA-3'

120

5'-ACC GGC TAT GGC ATT GCT ATC-3'
5'-GCC AGT GAG CCA GAG AGC TT-3'

NR2C

123

5'-GCA CAC CCA CAT GGT CAA GTT-3'
5'-TCC TTG CCT GCC ATG TAG TTG-3'

120

5'-TGC ACA CCC ACA TGG TCA AG-3'
5'-TGC CCG CCA TGT AGT TGA G-3'

NR2D

120

5'-GGC TCA GTG ACC GCA AGT TC-3'
5'-AGC TGT GCA TGT CGG GAT AGT-3'

134

5'-TGG CAT GAT TGG TGA GGT GTT-3'
5'-GTG CCA CCA TGA CGC TGA T-3'

GluR6

123

5'-GTG GCC GTT CAA CAG TTT CC-3'
5'-TGT GAG GCC TTC CCA ATG TG-3'

125

5'-ACC CTT GCA ACC CTG ACT CA-3'
5'-CCT GGT GGA GAG TGC TTT GG-3'

KA2

127

5'-GGA GGA GGA CCA TCG AGC TAA-3'
5'-CCT CCG TGT GGA CCA TAT GAA-3'

120

5'-GGC GGA TCA GAC CAA CAT TG-3'
5'-GGC TGC TTC GAC TGC ATG TAA-3'

mGluR2

132

5'-TCA ACG AGG CCA AGT TCA TTG-3'
5'-GGC TGA CTG ACA CGC ACA TG-3'

110

5'-CAT CAT CTG GCT GGC TTT CC-3'
5'-CAA GCA CCA CAG AGC CAC TGA-3'

mGluR3

120

5'-CAC TGG GCA GAA ACC TTA TCG-3'
5'-CCC TGG TTG CAT ATT CTT CAT TT-3'

121

5'-GCA TTG CTC GCA TCT TCG AT-3'
5'-ACG GAC ACC ATC ACA ATT TGC-3'

nNOS

120

5'-GGA GTC ACC CTG CGA ACG T-3'
5'-GGC AAG AGG GTC CAG TTA GGA-3'

121

5'-TGC TGC CTC TCC TGC TTC AG-3'
5'-AGC CCC AGG TCC TTA AAC CA-3'

171

Catalog # Hs99999903_m1

91

Catalog # Rn00667869_m1

GABAA-α6

108

Catalog # Hs00181301_m1

144

Catalog # Rn00573029_m1

GABAA-δ

71

Catalog # Hs00181309_m1

75

Catalog # Rn00568740_m1

TaqMan® Probe Sets
β-actin

c

Primer pairs listed according to species with forward primer above reverse primer. Includes amplicon size in bp. Amplicon sizes of gene of interest and
housekeeping genes were matched based on primer pairs and species. Probe set data may be obtained from Applied Biosystems.
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calculation with p<0.05 was considered significant.

Values from rat experiments

exceeding +2 SD from the mean were excluded from further analysis.

2.8 Quantitative In Situ Hybridization (qISH) and Immunohistochemistry (IHC)
GAD67 cRNA sense and antisense transcripts with incorporated
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S-UTP were

synthesized from cloned plasmids obtained from Niranjala Tillakaratne (UCLA).
Riboprobes were transcribed using T3 RNA polymerase (Promega; Madison, WI),
purified using RNeasy (Qiagen; Valencia, CA) and kept at -80oC until slides were
treated.

Frozen slides were placed at -20oC for 1 hour prior to fixation. ISH was performed
according to methods developed by Simmons, et al. (1989). Slides were hybridized with
1.5 x 106 cpm in a volume of 75 µL hybridization buffer and hybridized overnight at
55oC for 16 hours. After hybridization, slides were treated with RNase A and then
washed in decreasing SSC (20X stock solution; 0.3M sodium citrate, pH 7.0, 3M NaCl)
concentrations. Slides were then exposed to film for 24 hours to monitor adequate
hybridization and to determine proper exposure time to emulsion.

Following ISH, the slides were preincubated for 1 hour in 10% normal horse serum
(NHS) in TBS (50 mM Tris Base, pH 7.4, 0.9% NaCl), then incubated with mGluR2
monoclonal antibodies (AbCam; Cambridge, MA) at a 1:750 dilution in 1% NHS in TBS
for 16 hours at 4oC. Slides were washed and then incubated for 2 hours with biotinylated
horse-anti-mouse antibodies (Vector Labs; Burlingame, CA) at a 1:400 dilution in 1%
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NHS in TBS at room temperature. After another wash, the slides were treated with
Vector ABC Elite kit (Vector Labs) according to manufacturer’s directions and
developed using DAB as the chromogen.

Following ISH and IHC, slides were dipped in Kodak NTB2 emulsion (Kodak;
Rochester, NY) and exposed for 6 days at 4oC. Slides were then developed using Kodak
D-19 developer and fixer.

2.9 Imaging Autoradiographic Slides
After development of emulsion slides half of the slides were counterstained using
hematoxylin and eosin. Slides were photographed using an Olympus DP71 camera
(Olympus America Inc.; Center Valley, PA) attached to an Olympus BX60 microscope.
To count the number of cells per area, images were acquired using either a 10X objective
(for Golgi cell and Purkinje cell measurements) or at 20X (for basket/stellate cell
measurements). Images were acquired using a 60X objective to measure the number of
grains per cell.

2.10 ISH Data and Statistical Analysis
Pictures from slides were analyzed using ImagePro® Plus 4.0 (Media Cybernetics;
Bethesda, MD). Cell number per area was determined by counting cells at 10X for Golgi
and Purkinje cells, and 20X for basket/stellate cells by manually defining the region of
interest and counting the cells within that region. Area covered by grains per cell was
determined by creating a circle with a predetermined diameter, placing the circle over the
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cell of interest, and quantitating the area covered by grains within the area of the circle.
Diameters were set at 13 µm for basket/stellate cells, 25 µm for Golgi cells, and 30 µm
for Purkinje cells. More than 300 cells were counted per area and more than 25 cells
were evaluated for area covered by grains per cell. Values from slides were averaged
independently, entered into Prism 4.0 (GraphPad Software; San Diego, CA), and
analyzed using t-tests with a p<0.05 considered significant.
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Chapter 3
Results
3.1 Expression Data from Lateral Cerebellar Hemisphere of Patients with
Schizophrenia

3.1.1 GABAergic Marker Expression
Given the evidence of GABA deficits in schizophrenia, we sought to characterize the
condition of inhibitory interneurons in the cerebellum of patients. The reasons behind
these studies were two-fold: first to investigate the mechanisms underlying cerebellar
abnormalities in the patients and second to examine the nature and extent of GABA
dysfunction in different neuronal populations. Initial studies examined the expression of 7
markers of GABA function in the lateral cerebellar hemisphere of 13 pairs of patients
with schizophrenia and matched control subjects. Comparisons of transcript levels in
patients and matched control subjects by the Wilcoxon Signed Rank test revealed
significant decreases in the mRNA levels of GAD67 (S/C=0.62; p=0.0134), GAD65
(S/C=0.74; p=0.0171), and GAT-1 (S/C=0.57; p=0.0024) by 38%, 26% and 43%,
respectively, but not in Parvalbumin (Figure 3.1, Table 3.1). Patients with schizophrenia
also showed significant increases in the mRNAs for the granule cell extrasynaptic
GABAA receptor subunits α6 (S/C=1.44; p=0.0046) and δ (S/C=1.53; p=0.0002), relative
to β-actin mRNA, but no changes in the GABAA-β3 subunit mRNA, which is expressed
in various cells. ANCOVA analyses demonstrated that the changes in GAD65 transcript
levels were affected by age, PMI, and RIN as a group (p=0.1456; Table 3.2) and age
independently (p=0.508; Table 3.2). No other effects of age, PMI, or RIN were seen.
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Figure 3.1
a) Relative expression levels of GABAergic markers in the cerebellum of patients with
schizophrenia versus comparison subjects. Postsynaptic GABAA receptors α6 and δ are significantly
increased in patients while GAD67, GAD65, and GAT-1 are significantly decreased. Expression levels
are normalized to β-actin. b) Correlation of presynaptic GABA gene expression markers among
patients showing high correlations between GAD67, GAD65, and GAT-1. *p<0.05, **p<0.01,
***p<0.005.
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TABLE 3.1: Summary of Gene Expression Changes in Patients with Schizophrenia and Neuroleptic Treated Rats
Patients with Schizophrenia
Haloperidol Treated Rats
Clozapine Treated Rats
Gene of Interest
GABAergic Markers
GABAA-α6
GABAA-β3
GABAA-δ
GAD65
GAD67
GAT-1

Change
(%)

S/C
ratio

p value

Change
(%)

D/V
ratio

p value

Change
(%)

D/V
ratio

p value

+44
+16
+52
-26
-38

1.44
1.16
1.52
0.74
0.62

**0.0046
0.1099
***0.0002
*0.0171
*0.0134

nd
+33
nd
-19
+20

nd
1.33
nd
0.81
1.20

nd
*0.0126
nd
*0.0114
**0.0012

+25
+35
+25
+28
+31

1.25
1.35
1.25
1.28
1.31

***<0.0001
***<0.0001
***<0.0001
**0.0023
***<0.0001

-43

0.57

**0.0024

+17

1.17

*0.0205

-23

0.77

***<0.0001

-5
-6
-16
+7
+6

0.95
0.94
0.84
1.07
1.06

0.4973
0.2734
0.0681
0.5417
0.2734

+13
+23
+34
-15
-49

1.13
1.23
1.34
0.85
0.51

*0.0389
0.0803
0.1792
0.2776
***<0.0001

+34
-24
-20
-19
-10

1.34
0.76
0.80
0.81
0.90

***<0.0001
***<0.0001
**0.0035
***0.0005
0.1009

+23
+29
-27
-5
-28

1.23
1.29
0.73
0.95
0.72

*0.0327
***0.0002
**0.0024
0.5417
*0.0327

+26
-10
+32
nd
+11

1.26
0.90
1.32
nd
1.11

*0.0304
0.1271
***0.0008
nd
0.3364

+24
-23
+10
nd
-19

1.24
0.77
1.10
nd
0.81

***0.0005
***<0.0001
0.6163
nd
*0.0149

NMDA Receptor Subunits
NR1
NR2A
NR2B
NR2C
NR2D
Neuromodulators
GluR6
KA2
mGluR2
mGluR3
nNOS

Summary of gene expression data from patients with schizophrenia and rats treated with either haloperidol or clozapine. Deficits in GABAergic
markers and neuromodulator alterations are shown in patients with schizophrenia and represented as % change and Schizophrenic/Control ratio. Both
haloperidol and clozapine show positive effects on GAD67 expression with clozapine showing a more favorable profile for treating GABA deficits in
patients. Differences in human expression determined by pair-matched Wilcoxon Signed Rank test while rat differences analyzed by t tests *p<0.05, **p<0.01, ***p<0.0001.
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Table 3.2: ANCOVA Analysis of Gene Expression Data from Patients with Schizophrenia versus Comparison Subjects
Covariates
Age, PMI, and RIN

Age

PMI

RIN

df

F

p-value

df

F

p-value

df

F

p-value

df

F

p-value

GABAA-α
α6

4

3.9411

0.0154

2

7.2276

0.0037

2

6.4922

0.0058

2

6.3237

0.0065

GABAA-β
β3

4

1.5887

0.2142

2

2.6718

0.0905

2

3.0024

0.0694

2

2.6754

0.0902

GABAA-δ
δ

4

8.1258

0.0004

2

16.0097

0.0000

2

15.5406

0.0001

2

17.0303

0.0000

GAD67

4

4.9587

0.0057

2

8.4089

0.0018

2

8.0940

0.0022

2

9.5165

0.0010

GAD65

4

1.9133

*0.1456

2

3.3992

*0.0508

2

3.4659

0.0483

2

3.6836

0.0409

2

4.7911

0.0182

2

5.5030

0.0111

2

4.9390

0.0164

GluR6

4

2.6269

0.0636

KA2

4

6.4746

0.0015

2

13.8144

0.0001

2

14.1600

0.0001

2

13.7862

0.0001

NR1

4

0.4002

0.8062

2

0.2360

0.7916

2

0.6097

0.5520

2

0.5387

0.5907

NR2A

4

0.8853

0.4897

2

0.8429

0.4433

2

0.6725

0.5202

2

1.8562

0.1789

NR2B

4

3.3833

*0.0275

2

2.6036

0.0957

2

1.3834

0.2708

2

3.4896

*0.0474

NR2C

4

0.4675

0.7589

2

0.4478

0.6445

2

0.9940

0.3854

2

0.4438

0.6470

NR2D

4

0.7347

0.5786

2

1.0169

0.3774

2

0.6777

0.5176

2

0.4655

0.6336

mGluR2

4

1.9597

*0.1378

2

3.3063

*0.0546

2

3.6760

0.0412

2

3.5922

0.0439

mGluR3

4

1.3178

0.2958

2

0.4890

0.6195

2

1.1630

0.3303

2

0.8296

0.4488

nNOS

4

3.0461

0.0398

2

3.9291

0.0340

2

4.6694

0.0199

2

4.4273

0.0236

Parvalbumin

4

0.3418

0.8467

2

0.1210

0.8866

2

0.1603

0.8529

2

0.7257

0.4947

GAT-1

4

3.8619

0.0167

2

7.1040

0.0040

2

6.4269

0.0061

2

6.7414

0.0050

Summary of analysis of covariance (ANCOVA) with condition as a fixed factor and age, PMI, and RIN as covariates. The covariates were
analyzed as a group and independently. Changes in GAD65 and mGluR2 were shown to be non-significant while NR2B was shown to be
significant when age, PMI, and RIN were accounted for. When analyzed independently, GAD65 and mGluR2 showed effects of age while
NR2B was influenced by RIN.
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To examine possible interactions in patterns of gene expression in patients with
schizophrenia and control subjects, mRNA levels were analyzed by correlating transcript
expression per group using Spearman’s ρ.

In the schizophrenic group, positive

correlations included GAD67 with GAD65 (r=0.922; p <0.001) and GAT-1 (r=0.797;
p=0.001), GAD65 with GAT-1 (r=0.770; p=0.002) (Figure 3.1), and GABAA-α6 with
GABAA-β3 (r=0.610; p=0.027). Control subjects also showed a correlation in GAD67
with GAT-1 (r=0.646; p=0.017). No significant negative correlations were observed
among the GABAergic markers studied.

3.1.2 NMDA Receptor Subunit Expression
In addition to GABA deficits, NMDA dysfunction has been reported in patients with
schizophrenia (Akbarian et al., 1996b). Analyses of the levels of the NR1 and NR2A –
NR2D subunits of the NMDA receptor revealed no significant changes (Table 3.1). The
only observed change was a trend towards decrease in the Golgi cell selective subunit
NR2B (Scherzer et al., 1997) (S/C=0.84; p=0.0681). Furthermore, the levels of NR2B in
the schizophrenic population were positively correlated with NR1 (r=0.553; p=0.050),
NR2A (r=0.553; p=0.050), and NR2D (r=0.663; p=0.014) (Figure 3.2).

ANCOVA

analyses showed significant contributions of age, PMI, or RIN to NR2B as a group
(p=0.0275; Table 3.2) while RIN affected NR2B independently (p=0.0474; Table 3.2).
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Figure 3.2
a) Relative expression levels of NMDA receptor subunits in the cerebellum of patients
with schizophrenia versus comparison subjects. No significant changes are seen in any of the subunits
examined. Expression levels are normalized to β-actin. b) Correlation of NMDA receptor subunits
among patients showing high correlations between NR2B and NR1, NR2A, and NR2D. *p<0.05.
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3.1.3 Cerebellar Neuromodulator Expression
GABA release onto cerebellar granule cells is regulated at the level of the cerebellar
glomerulus, where pontine mossy fiber and Golgi cell outputs synapse onto granule cell
dendrites in a closed structural and functional unit.

We therefore, examined major

modulatory factors in this unit that could contribute to decreases in GABA
neurotransmission on granule cells. Of these factors, we observed significant decreases
in transcript levels of neuronal nitric oxide synthase (nNOS) (S/C=0.72; p=0.0327),
present in granule cells (Baader and Schilling, 1996), and the Golgi cell specific
metabotropic glutamate receptor mGluR2 (Berthele et al., 1999) (S/C=0.73; 0.0024), but
not in the ubiquitously-expressed metabotropic glutamate receptor mGluR3 (Figure 3.3).
Interestingly, both NO production and presynaptic mGluR2 receptor activation modulates
GABA release from Golgi cells (Geurts et al., 2003; Wall, 2003). Moreover, we found
significantly increased levels of the glutamatergic kainate receptor subunits GluR6
(S/C=1.23; p=0.0327) and the granule cell-specific subunit KA2 (Porter et al., 1997)
(S/C=1.29; 0.0002) and a positive correlation between mGluR2 and GluR6 mRNA levels
(r=0.709; p=0.007) in the schizophrenic patient group. ANCOVA analyses showed that
the changes in transcript levels are of mGluR2 are affected by age, PMI, and RIN as a
group (p=0.1378; Table 3.2) and age independently (p=0.0546; Table 3.2).

3.1.4 Correlations of Transcripts Levels of Golgi Cell Genes, Granule Cell Genes, and
Local Cerebellar Circuitry Components
To investigate further the functional integrity of the cerebellar glomerulus in
schizophrenia, interactions between specific markers for Golgi cells, granule cells, or the
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Figure 3.3
a) Relative expression levels of cerebellar neuromodulators of GABA release at the
cerebellar glomerulus in patients with schizophrenia versus comparison subjects. Significant increases
were seen in kainate receptor subunits Golgi and granule cell GluR6 and granule cell specific KA2
while significant decreases were shown in Golgi cell specific mGluR2 and granule cell nNOS.
Expression levels are normalized to β-actin. b) Correlation analysis between markers expressed in the
Golgi-granule cell circuit show high correlations between GluR6 with mGluR2 and NR2B and between
nNOS and NR2B. * p<0.05, **p<0.01, ***p<0.001.

34

Golgi-granule cell circuit were analyzed.

Examining genes from the schizophrenic

population that are expressed in Golgi cells, we found positive correlations between the
Golgi cell selective NMDA receptor subunit NR2B with GAD67 (r=0.922; p<0.001),
GAD65 (r=0.854; p<0.001), and GAT-1 (r=0.671; p=0.012), and mGluR2 with GAD65
(r=0.575; p=0.040), all of which were decreased in the patients. In addition, transcripts
expressed in granule cells showed correlations between NR2C with GABAA-α6
(r=0.639; p=0.019), GABAA-β3 (r=0.722; p=0.005), GABAA-δ (r=0.652; p=0.016), and
KA2 (r=0.726; p=0.005), which were all increased in the patient population. Finally, we
found that nNOS correlated with GABAA-β3 (r=0.757; p=0.003), GABAA-α6 with
GluR6 (r=0.659; p=0.014), and KA2 with GABAA-δ (r=0.600; p=0.030).

Positive correlations between components of granule cell-Golgi cell circuitry included
GABAA-α6 with mGluR2 (r=0.797; p<0.001) and NR2B with GABAA-β3 (r=0.600;
p=0.030), GluR6 (r=0.594, p=0.032), and nNOS (r=0.624; p=0.023).

Significant

negative correlations were observed for GAT-1 with NR2C (r=-0.553, p=0.050) and KA2
(r=-0.779; p=0.002), presumably reflecting a compensatory mechanism to increase
GABA neurotransmission in the synaptic cleft.

3.2 Medication Effects on Gene Expression in Haloperidol and Clozapine Treated
Rats
All patients were taking antipsychotics at the time of death (Table 2.1). Analysis of gene
expression levels between patients who were administered atypical versus typical
antipsychotics showed a significant increase in GAD67 (p=0.0334 using Mann-Whitney
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Rank Sum test; Supplementary Figure A.5.4) and NR2A (p=0.0140; Supplementary
Figure A.5.9) gene expression. These findings suggested that medication type (typical
versus atypical) may have an effect on gene expression levels in patients. Therefore, we
analyzed the levels of the same mRNAs in the cerebellum of rats treated with
haloperidol, the classic typical neuroleptic, given at a dose of about 1 mg/kg/day for six
months. As shown in Table 3.1, we found significant increases in GABAA-β3, GAD67,
and GAT-1 in these rats. On the other hand, a significant decrease was seen in the
expression of GAD65. NMDA receptor subunit expression showed only a significant
increase in NR1 and a significant decrease in NR2D transcript levels. Expression levels
in cerebellar neuromodulators GluR6 and mGluR2 showed significant increases. In
contrast, KA2 and nNOS mRNA levels were not different between control and treated
groups.

To examine the effects of atypical medications, rats were treated with clozapine,
administered for 21 days at a dose of 10/mg/kg/day. As shown in Table 3.1, these
animals showed increased cerebellar mRNA levels of GABAergic markers GABAA-β3,
GAD67, and GAD65, while GAT-1 expression was significantly decreased. For NMDA
receptor subunit expression, NR1 was significantly increased whereas NR2A, NR2B, and
NR2C were all decreased, and NR2D showed no change between groups. Finally, the
cerebellar neuromodulator GluR6 was significantly increased, in contrast to decreased in
KA2 and nNOS, but not mGluR2 mRNAs.

Overall, our results indicate that the

antipsychotic medication could compensate, in part, for the decreased level of GABA

36

synthesizing enzymes and Golgi cell-specific marker mGluR2 that we observed in the
patient samples.

3.3 Expression Data from Lateral Cerebellar Hemisphere of PCP Treated Rats

3.3.1 GABAergic Marker Expression
Given the evidence that PCP elicits many of the behaviors seen in schizophrenia (for
review see Morris et al., 2005), we sought to characterize GABA dysfunction in
inhibitory interneurons from the cerebella of these rats. Expression of six markers of
GABA function in the lateral cerebellar hemisphere of PCP treated rats and paired saline
control rats were initially examined using qRT-PCR. Transcript levels of presynaptic
GABA signaling components GAD67 (P/S=0.89; p=0.0060), GAD65 (P/S=0.82;
p=0.0023), and GAT-1 (P/S=0.82; p=0.0242) were shown to be significantly decreased in
PCP rats versus controls by 11%, 18%, and 17% respectively (Figure 3.4, Table 3.3)
using t-tests.

Contrastingly, postsynaptic GABA receptor subunits GABAA-α6

(P/S=1.55; p=0.0001), GABAA-β3 (P/S=1.28; p=0.0024), and GABAA-δ (P/S=1.55;
p=0.0002) were significantly upregulated in the PCP rats.

The overall GABAergic

expression profile in the cerebellum showed a decrease in marker expression
presynaptically while postsynaptic expression of markers was increased.

3.3.2 NMDA Receptor Subunit Expression
PCP acts as an open channel NMDA receptor antagonist (for review see Morris et al.,
2005) and preferentially antagonizes GABAergic interneurons
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Figure 3.4
Relative expression levels of GABAergic markers in the cerebellum of PCP
treated rats versus saline controls. Postsynaptic GABAA receptors α6, β3, and δ are
significantly increased in PCP rats while GABA synthesizing enzymes GAD67 and GAD65,
and the reuptake transporter GAT-1, are significantly decreased. Expression levels
normalized to β-actin. *p<0.05, **p<0.01, ***p<0.005.
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TABLE 3.3: Summary of Gene Expression Changes in PCP Treated Rats
Change (%)
P/S ratio
p value
Gene of Interest
GABAergic Markers
GABAA-α6
GABAA-β3
GABAA-δ
GAD65
GAD67
GAT-1

+55
+28
+55
-18
-11

1.55
1.28
1.55
0.82
0.89

***0.0001
**0.0024
***0.0002
**0.0023
**0.0060

-17

0.83

*0.0242

-5
0
-22
+9
-36

0.95
1.00
0.78
1.09
0.74

0.1324
0.0952
**0.0049
0.6822
**0.0076

-16
+39
+37
-6
+15

0.84
1.39
1.37
0.94
1.15

**0.0014
***<0.0001
0.0610
0.3612
0.1862

NMDA Receptor Subunits
NR1
NR2A
NR2B
NR2C
NR2D
Neuromodulators
GluR6
KA2
mGluR2
mGluR3
nNOS

Summary of gene expression changes seen in PCP treated rats versus saline controls.
Decreases in mRNA levels of GAD65 and GAD67 are seen in the cerebellum of PCP
treated rats versus saline controls as shown by both percent change and PCP/Saline
(P/S) expression ratio. All other gene changes are involved in GABAergic
transmission between Golgi cells and granule cells. Differences in expression
determined by t test - *p<0.05, **p<0.01, ***p<0.0001.
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(Grunze et al., 1996; Homayoun and Moghaddam, 2007). To determine its effects on
NMDA receptor expression, we evaluated expression levels of cerebellar NMDA
receptor subunits. Decreased mRNA levels of two subunits, the Golgi cell specific
NR2B subunit (Scherzer et al., 1997; Misra et al., 2000) (P/S=0.78; p=0.0049) and NR2D
(P/S=0.74; p=0.0076) were the only significant changes seen among NMDA receptor
subunits. Interestingly, NR2B and NR2D are co-localized to Golgi cells (Brickley et al.,
2003), further suggesting that these cells may be preferentially affected by PCP. In
contrast, the mRNA levels of NR1 (P/S=0.95; p=0.1324), NR2A (P/S=1.00; p=0.0952),
and NR2C (P/S=1.09; p=0.6822) subunits were not significantly altered (Figure 3.5,
Table 3.3).

3.3.3 Cerebellar Neuromodulator Expression
Considering the changes in expression of GABAergic markers and NMDA receptor
subunits seen in our samples were consistent with deficits Golgi-granule cell
communication, we examined major modulatory components involved in GABAergic
transmission to granule cells. Here we observed a significant decrease in kainate receptor
subunit GluR6 (P/S=0.84; p=0.0014), present in both Golgi and granule cells (Porter et
al., 1997; Bureau et al., 2000), and a contrasting increase in the granule cell specific KA2
subunit (P/S=1.39; p<0.0001) (Porter et al., 1997; Pemberton et al., 1998). We did not
find any changes in expression of metabotropic glutamate receptors mGluR2 (P/S=1.37;
p=0.0610), which is present presynaptically solely in Golgi cells (Berthele et al., 1999;
Watanabe and Nakanishi, 2003), nor in mGluR3 (P/S=0.94; p=0.3612), which is mainly

40

Relative mRNA Levels

10

Saline
PCP

8
6

**

4

**

2

2D
R
N

R
N

R
N

2C

2B

2A
R
N

N

R
1

0

Figure 3.5
Relative expression levels of NMDA receptor subunits in the cerebellum of
PCP treated rats versus saline controls. The Golgi cell specific subunit NR2B along with the
interneuron marker NR2D are both significantly decreased in PCP treated rats. Expression
levels normalized to β-actin. **p<0.01.

41

glial (Berthele et al., 1999). Additionally, postsynaptic nNOS (P/S=1.15; p=0.1862)
levels were also unchanged (Figure 3.6, Table 3.3).

3.4 Decreased GAD67 Expression in Golgi Cells of the Cerebellum
The GABA hypothesis of schizophrenia states that GABAergic deficits in specific
subsets of interneurons are pathophysiological hallmarks of the disease (for review see
Lewis et al., 2005). Chronic low dose administration of PCP preferentially inhibits
GABAergic interneurons (Grunze et al., 1996; Jackson et al., 2004; Homayoun and
Moghaddam, 2007) and has been proposed as an animal model of schizophrenia,
mimicking many of the molecular findings seen in patients (Abe et al., 2000; Kim et al.,
2000a; Cochran et al., 2003). Since many of the alterations seen in cerebellar transcript
levels implicate deficient Golgi cell to granule cell inhibitory neurotransmission, we
performed quantitative in situ hybridization to localize the changes seen in GAD67
expression using qRT-PCR to a particular cell type. Analysis of Golgi cells dually
stained with GAD67 riboprobe and mGluR2 antibody, a Golgi cell specific marker
(Figure 3.7a, c), showed an overall decrease in Golgi cell numbers (P/S=0.77; p=0.0014)
in PCP treated rats versus controls, but not in basket/stellate cells of the molecular layer
(P/S=0.96; p=0.4586) or in Purkinje cells (P/S=0.93; p=0.5262) (Figure 3.7b).
Furthermore, analysis of the area covered by grains per cell type showed that PCP rats
expressed significantly less GAD67 in Golgi cells (P/S=0.66; p=0.0058), but remained
unchanged in basket/stellate cells (P/S=0.97; p=0.8319) and in Purkinje cells (P/S=0.93;
p=0.5191) (Figure 3.7d). These results point to Golgi cells as the cells primarily affected
by chronic intermittent exposure to a low dose of PCP.
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Figure 3.6
Relative expression levels of cerebellar neuromodulators of GABA release in
the cerebellar glomerulus of PCP treated rats versus saline controls. Granule cell specific
KA2 is significantly increased with granule and Golgi cell specific GluR6 is significantly
decreased. Expression levels normalized to β-actin. **p<0.01, ***p<0.005.
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Figure 3.7
Quantitative in situ hybridization of GAD67 transcript expression levels in the cerebellar
cortex of PCP treated rats. a 10X magnification of a cerebellar folium showing GAD67 ISH (grains)
with mGluR2 IHC (brown). Golgi cells can be well visualized in the granule cell layer, Purkinje cells in
the Purkinje cell layer, and basket and stellate cells in the molecular layer. Bar represents 50 µm. b 40X
magnification representing inset in panel a. Distinction can be made between Golgi cells (arrowheads)
and Purkinje cells (arrows). Basket and stellate cells are also shown (asterisks). Bar represents 50 µm. c
Percentage of GAD67 expressing cells in the granule cell layer (GCL), molecular layer (ML), and
Purkinje cell layer (PCL) of the cerebellum. All values normalized to saline control animal values. d
Density of GAD67 silver grains in cerebellar Golgi (GoC) cells, basket (BC) and stellate (SC) cells, and
Purkinje (PC) cells. **p<0.01.
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Chapter 4
Discussion
4.1 Patients with Schizophrenia
An increasing number of experimental studies support the hypothesis that GABA
mediated neurotransmission is deficient in subsets of interneurons in patients with
schizophrenia (for reviews see (Benes and Berretta, 2001; Lewis et al., 2005; Akbarian
and Huang, 2006). While the effects of GABA mediated excitatory disinhibition have
been well characterized in the PFC (Akbarian et al., 1995; Volk et al., 2000; Hashimoto
et al., 2003) and limbic system (Heckers et al., 2002; Woo et al., 2004) of patients with
schizophrenia, few studies have examined these deficits in the cerebellum (Guidotti et al.,
2000; Fatemi et al., 2005). Analysis of post-mortem tissue from the lateral cerebellar
hemisphere of patients with schizophrenia clearly demonstrates GABA deficits, which,
along with altered expression of neuromodulators of granule cell activity, implicate a
selective deficit in local granule cell-Golgi cell communication. A dysfunction in this
local network is expected to have consequences in the function of both cerebellar microand macro-circuitry. Deficient tonic Golgi cell modulation may cause disinhibition of
granule cells, as marked by increases in activity-dependent genes (Paz et al., 2006), and
could disrupt cerebellar output by Purkinje cells. This disrupted output may, in turn,
have a significant effect on other brain regions in the cortico-cerebellar-thalamic-cortical
circuit, which includes the PFC (Andreasen et al., 1999).
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4.1.1 GABAergic Marker Deficits in Patients with Schizophrenia
A number of discrete GABAergic interneurons reside in the cerebellum, most notably
Golgi cells in the granule layer and basket and stellate cells in the molecular layer. While
basket and stellate cells provide feed forward inhibition from granule cells to Purkinje
cells, Golgi cells provide the sole source of feedback inhibition to granule cells (for
review see (Ito, 2006).

Together with Purkinje cells, these GABAergic interneurons

express the GABA synthesizing enzymes GAD65 and GAD67, which are encoded by
distinct genes (Erlander et al., 1991) and exhibit different subcellular localizations
(Esclapez et al., 1994).

Our findings (Figure 3.1) indicate that the levels of both

transcripts are decreased in patients versus control subjects, suggesting that GABA
synthesis may be impaired in patients. We also found that transcript levels between the
two enzymes are significantly correlated in the schizophrenic population (Figure 3.1). In
agreement with our observations, Fatemi and colleagues (Fatemi et al., 2005)
demonstrated decreases in the levels of both proteins in the cerebellum of a separate
cohort of patients with schizophrenia, further supporting the idea of an overall deficit in
GABA neurotransmission in this illness.

While GABA synthesis cannot be directly measured in post-mortem tissue, other markers
can be investigated to infer whether GABAergic synaptic transmission is reduced. For
example, deceased levels of transcripts encoding for the presynaptic GABA transporter,
GAT-1 (Figure 3.1) may reflect a compensatory attempt to increase synaptic GABA. In
adults Golgi and basket/stellate cells express GAT-1 while Purkinje cells and glia do not
(Takayama and Inoue, 2005), suggesting that GAT-1 deficits may be restricted to specific
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GABAergic interneurons. This is consistent with a similar decrease in GAT-1 observed
in a specific subpopulation of GABAergic interneurons in association with GAD67
deficits in the PFC of patients with schizophrenia (Volk et al., 2001). Interestingly, the
calcium binding protein parvalbumin, which has been shown to label GABAergic
interneurons that are decreased in the PFC of patients with schizophrenia (Hashimoto et
al., 2003), was not decreased in our patient population.

Parvalbumin is expressed

primarily in Purkinje and basket/stellate cells, but only in a small subpopulation of Golgi
cells (Bastianelli, 2003).

Conversely, the significant increases in the expression of

extrasynaptic GABAA receptor subunits α6 and δ (Figure 3.1) suggest that a
compensatory mechanism may occur to increase GABA receptivity by the granule cell in
response to decreased GABA synthesis and release. These findings strongly suggest
deficits selective to Golgi cells as compared to other GABAergic interneurons in the
cerebellum.

4.1.2 NMDA Receptor Expression in Patients with Schizophrenia
A competing, but not mutually exclusive, hypothesis of schizophrenia implicates
dysfunction of glutamatergic NMDA receptors and proposes that deficits in NMDA
receptor mediated neurotransmission account for the cellular abnormalities and aberrant
signaling seen in patients (Akbarian et al., 1996b).

Furthermore, recent studies

demonstrate that GABAergic interneurons are more vulnerable to NMDA receptor
hypofunction (Grunze et al., 1996; Homayoun and Moghaddam, 2007). To get further
insights into the subtypes of GABAergic interneurons that are primarily affected in the
cerebellum we examined the expression of cell-selective NMDA receptor subunits
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(Scherzer et al., 1997). While each cell type expresses the obligatory NR1 subunit,
Purkinje cells mainly express NR2A, Golgi cells NR2B, granule cells NR2C, and
basket/stellate cells NR2D. Although none of these subunits were significantly changed
in the patients, the levels of NR2B subunit showed a trend towards decrease in this cohort
(p=0.0681). Moreover, the expression of the NR2B subunit was strongly correlated with
NR2D, both of which colocalize extrasynaptically in Golgi cells and might reflect altered
modulation of glutamatergic tone on Golgi cells (Brickley et al., 2003). Additionally,
NR2B subunit expression correlated strongly with GAD65 and GAT-1 expression in the
patients and with GAD67 in both patients and controls (Figure 3.2). These findings
further point to the Golgi cell as the predominately affected cerebellar interneuron in
schizophrenia.

4.1.3 Neuromodulator Alterations in Patients with Schizophrenia
Given that Golgi interneurons control granule cells activity, we examined mRNA levels
of proteins modulating GABA neurotransmission from Golgi to granule cells. GABA
release by Golgi cells is regulated by various factors in both Golgi and granule cells
including Golgi cell specific mGluR2 (Berthele et al., 1999) and nNOS located in granule
cells (Wall, 2003). Activation of both systems normally decreases GABA release by
Golgi cells, and both were shown to be decreased in the patient population (Figure 3.2),
again presumably compensating for decreased levels of GABA in the synapse. On the
other hand mGluR3, which is expressed in most cell types including glia (Berthele et al.,
1999), was not changed in patients. Additionally, decreased levels of kainate receptor
subunits GluR6 and KA2 mRNAs have been previously reported in the prefrontal cortex
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and hippocampus of patients with schizophrenia (Porter et al., 1997; Meador-Woodruff et
al., 2001). This contrasts with the increased mRNA levels of GluR6 and KA2 seen in our
cohort of patients. Since these markers are expressed in granule cells and these cells
show increased expression of activity dependent-genes in the same group of patients (Paz
et al., 2006), it is possible that the changes in kainate receptor subunits may reflect a
change in basal granule cell activity. Additionally, activation of presynaptic kainate
receptors has been shown to increase GABA release (Mathew et al., 2008), further acting
as compensatory processes for decreased GABA signaling. A model summarizing the
changes in gene expression and putative cerebellar microcircuit alterations is shown in
Figure 4.1.

An alteration in GABA neurotransmission between Golgi and granule cells is further
evidenced by the positive correlations found only in patients between the Golgi specific
markers mGluR2 and NR2B with the kainate receptor GluR6 subunit (Figure 3.2).
Moreover, the positive correlation between nNOS with NR2B (Figure 3.2), together with
the negative correlations between GAT-1 with granule cell specific NR2C and KA2, and
the lack of a strong correlation between GABAA-δ and mGluR2 in the patients (data not
shown), suggest a defect in modulation of GABA release by Golgi cells and increased
firing of granule cells.

4.1.4 Medication Effects on Gene Expression
Our gene expression findings in patients point to dysfunctional regulation of GABA
release between Golgi and granule cells, but do not take into account any effects of
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↑ GAP-43
↑ BDNF
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↑ GABAA-δ
↑ GluR6
↑ KA2
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↓ mGluR2
↓ NR2B?
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Figure 4.1: Summary of Gene Alterations in the Cerebellum of Patients with Schizophrenia. Note
decreased GABA gene expression in Golgi cells and increased modulatory gene expression in Golgi and
granule cells. GrC-granule cells; GoC-Golgi cells; BC-basket cells; SC-stellate cells; PC-Purkinje cells;
GL-cerebellar glomerulus; MF-mossy fibers (from pontine nuclei); CF-climbing fibers (from inferior
olive).
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antipsychotic medication. To address this issue, we examined the levels of the same
transcripts in rats treated with either haloperidol (Bustillo et al., 2006) or clozapine (Bai
et al., 2004). While antipsychotic medications have been shown to affect gene expression
in several brain regions, these alterations have previously not been reported for the
cerebellum (Zink et al., 2004a; Zink et al., 2004b). Based on our results (Table 3.1),
clozapine seems to have a more beneficial effect on gene expression of all modulatory
components in the local cerebellar circuit leading to increased GABA in the synaptic cleft
than does haloperidol, although both medications were effective in increasing GAD67.
Our results support the idea that combining different types of antipsychotics with
GABAA receptor agonists and mGluR2 antagonists may have enhanced benefits for
treating the underlying GABA-glutamate pathophysiology of schizophrenia.

4.1.5 Summary of GABAergic Deficits in Patients with Schizophrenia
In conclusion, we found that the expression of multiple GABAergic markers is decreased
in the lateral cerebellar hemispheres of patients with schizophrenia versus pair-matched
controls and that these deficits are most likely localized to Golgi cells. Additionally, both
typical and atypical medications exert a level of influence on gene expression in this
system.

Overall, patient mRNA expression data points to GABA signaling deficits

between Golgi and granule cells, possibly causing increased granule cell activity and
disinhibition of glutamatergic signaling in the cerebellum leading to aberrant cerebellar
output. These changes may underlie not only the alterations in cerebellar blood flow
observed in the patients but also, and most importantly, the clinical symptoms associated
with abnormal cerebellar function in schizophrenia (Ho et al., 2004).
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4.2 PCP Treated Rats
Considering an increasing number of studies have characterized GABA expression
deficits in patients with schizophrenia (for reviews see Benes and Berretta, 2001; Lewis
et al., 2005; Akbarian and Huang, 2006), it is important that some of these deficits are
reproduced in an animal model. One such model is a chronic low dose PCP exposure
(Cochran et al., 2003) which was shown to reproduce decreases in parvalbumin mRNA in
GABAergic interneurons seen in the PFC of patients with schizophrenia. Therefore, we
chose this model for our studies. By chronic administration of low-dose PCP to rats, we
demonstrated the decreased expression of markers of GABA mediated neurotransmission
in the cerebellum of this animal model mimic the alterations found in the same markers
in patients with schizophrenia .

Additionally, we localized the decrease in GAD67

expression to a specific subtype of cerebellar GABAergic interneuron, the Golgi cell.
Based upon our patient data and our findings in PCP-treated rats, we propose that Golgi
cells are vulnerable to the effects of NMDA hypofunction.

Since Golgi cells are

responsible for negative feedback on excitatory granule cell firing, dysfunctional Golgi
cell signaling may cause granule cell disinhibition and disrupted cerebellar output to
other brain regions, including those implicated in schizophrenia, such as the PFC.

4.2.1 Golgi-Granule Cell Signaling – Tonic Inhibition
It has been well established that Golgi cells are responsible for tonic inhibition of granule
cells (De Schutter et al., 2000; Rossi et al., 2003). This inhibitory tone is thought to be
imparted by GABA release due to autorhythmic activity (Forti et al., 2006) and mediated
through GABA binding to high affinity GABAA-α6/δ containing receptors located
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extrasynaptically (Hamann et al., 2002; Geurts et al., 2003; Fritschy and Panzanelli,
2006). This signaling occurs in a unit named the cerebellar glomerulus, comprised of the
Golgi cell axon-granule cell-pontine mossy fiber axon synapses (for review see De
Schutter et al., 2000). Here extracellular GABA concentrations are regulated by the
neuronal presynaptic transporter GAT-1, which also effectively ends phasic GABA
transmission (Morara et al., 1996). Our findings show decreased levels of GAD67 and
GAD65 expression (Figure 3.4, Table 3.3, and Figure 3.7b, d), indicating deficient GABA
production. These findings, along with decreased GAT-1 expression and increased levels
of GABAA receptor subunits α6, β3, and δ (Figure 3.4, Table 3.3), point to aberrant
GABAergic neurotransmission between Golgi cells and granule cells in PCP treated rats.
Insufficient GABA tone decreases the threshold of activation for granule cells, allowing
for increased granule cell activity and increased expression of activity dependent genes,
such as GABAA-δ (Salonen et al., 2006) and the granule cell specific kainate receptor
subunit KA2 (Feligioni et al., 2006).

4.2.2 Golgi-Granule Cell Signaling – Phasic Inhibition
Golgi cells also regulate granule cell activity in a phasic manner, receiving excitatory
input from granule cell parallel fibers and then providing inhibitory feedback, functioning
in a negative feedback system (for review see De Schutter et al., 2000). Release of
glutamate by mossy fiber afferents excites granule cells while inhibiting GABA release
from Golgi cells through presynaptic binding of mGluR2/3 receptors (Geurts et al.,
2003), while postsynaptic mGluR2 activation by glutamate release from parallel fibers
also inhibits downstream GABA release (Watanabe and Nakanishi, 2003).
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Further

inhibition of GABA neurotransmission takes place when granule cells release nitric oxide
(NO), synthesized by the activity dependent nNOS (Wall, 2003), decreasing GABA
release from Golgi cells in a retrograde manner.

Hence, simultaneous granule cell

activation by glutamate and inhibition of Golgi cell GABA release increases granule cell
activity (Chadderton et al., 2004).

While our findings in patients with schizophrenia show perceived compensatory
decreases in mGluR2 and nNOS , the PCP rat model failed to replicate these deficits.
This could be due, in part, to increased NO production due to PCP administration (Wiley,
1998; Wass et al., 2006). Conversely, mGluR3 expression is not changed (Figure 3.6) as
expected since it is glial (Berthele et al., 1999). However, decreased levels of GluR6
(Figure 3.6, Table 3.3), a Golgi and granule cell selective kainate receptor forming
functional homomeric channels (Bureau et al., 2000) and modulating GABA release
presynaptically (Mathew et al., 2008), suggest alternative methods of compensation for
decreased GABA release and further implicate Golgi cells as dysfunctional. The deficits
seen in Golgi cells, therefore, may lead to decreased tonic and phasic inhibition,
deregulating granule cell transmission to Purkinje cells and ultimately contributing to
aberrant cerebellar output.

The interaction between parallel fibers and Golgi cells is non-synaptic and has a low
probability of glutamate release (Dieudonne, 1998). This indicates that Golgi cells main
function is tonic, not phasic, inhibition (Rossi et al., 2003). However, glutamate is
released onto Golgi cells and functions partly through NMDA receptors. Golgi cell
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NMDA receptors consist of the obligatory NR1 subunit along with Golgi cell specific
NR2B in synaptic channels (Misra et al., 2000) and heterotetramers containing both
NR2B and NR2D at extrasynaptic sites (Brickley et al., 2003). We found decreased
expression of both NR2B and NR2D subunits (Figure 3.5, Table 3.3), suggesting
preferential antagonism of Golgi cell NMDA receptors.

This is not surprising

considering GABAergic interneurons in the hippocampus and PFC are selectively
affected by PCP administration (Grunze et al., 1996; Homayoun and Moghaddam, 2007).
Molecular layer basket and stellate interneurons also express NR2D (Berthele et al.,
1999), but do not show deficits in GAD67 expression (Figure 3.7c, d) and, thus, are not
affected by low dose PCP administration.

4.2.3 Purkinje Cells
Granule cells ultimately synapse on Purkinje cells, the sole source of output from the
cerebellar cortex. Purkinje cells are GABAergic projection neurons that integrate signals
from multiple inputs from parallel fibers, basket/stellate interneurons, and climbing
fibers, and send the sole cerebellar output signal to deep cerebellar nuclei (Sastry et al.,
1997). Our results suggest Purkinje cells are not directly affected by PCP administration,
as seen by the unchanged levels of Purkinje cell selective NR2A (Figure 3.5, Table 3.3)
and GAD67 (Figure 3.7d), and the decreased expression of GAT-1 (Figure 3.4, Table 3.3),
which is not expressed in Purkinje cells (Takayama and Inoue, 2005). However, Purkinje
cell output may be irregular due to increased granule cells activity caused by disinhibition
from deficient Golgi cell GABA neurotransmission. These deficits may desynchronize
Purkinje cell input, ultimately leading to aberrant cerebellar output.
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4.2.4 Summary of GABAergic Deficits in PCP Treated Rats
In conclusion, we have shown that chronic low-dose administration of PCP in rats models
the GABA neurotransmission deficits seen in patients with schizophrenia . Furthermore,
we localized these changes to Golgi cells, a subset of cerebellar inhibitory interneurons,
critical for controlling granule cell output to Purkinje cells. Our findings indicate that
GABAergic neurotransmission in the cerebellum mediated by Golgi cells is defective.
Aberrant cerebellar signaling, through its connections to the PFC, may be contributing to
the cognitive deficits seen in the patients.

4.3 Translational Implications
Understanding the pathophysiology of schizophrenia is crucial in developing more
effective treatments. Current psychopharmacotherapeutical interventions are successful
in treating positive symptoms, but do not treat negative or cognitive symptoms
effectively (Lewis et al., 2004; Harvey et al., 2005), which are the better prognosticators
for patient outcomes (Breier et al., 1991; Milev et al., 2005). This is most likely due to
the fact that typical and atypical antipsychotics were developed to treat excessive
dopaminergic signaling. While it is apparent that patients exhibit problems in dopamine
neurotransmission, it is unlikely that dopamine dysfunction is the underlying cause of the
disease. Additionally, clinical studies have shown that typical and atypical antipsychotics
show no differences in quality of life, treatment of symptoms, and cost (Jones et al.,
2006).

Moreover, glutamatergic agents, such as glycine or D-cycloserine, have not

proven useful in reversing the negative or cognitive deficits (Buchanan et al., 2007).
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Furthermore, many of the medications available have unwanted side effects that preclude
patients from adhering to treatment regimens. In essence, more effective therapies with
less severe side effects are the short-term goal for clinical schizophrenia. The ultimate
goal is eventually finding a cure for this disease.

In light of recent data, including our own studies (Akbarian et al., 1995; Guidotti et al.,
2000; Hashimoto et al., 2003; Fatemi et al., 2005; Benes et al., 2007), it is becoming
more clear that GABAergic deficits are more widespread and contribute more to the
underlying etiology of schizophrenia. With this in mind, more therapeutic options geared
towards treating the regionally specific deficits seen in GABA signaling need to be
developed and tested. Benzodiazepine-like GABA modulators, such as α2- and α5selective GABAA receptor agonists or benzodiazepine antagonists (Lewis et al., 2004;
Guidotti et al., 2005; Menzies et al., 2007), are showing promise in animal and human
studies.

However, truly effective treatments cannot be developed until the

pathophysiological mechanisms that underlie schizophrenia are discovered. Our study
provides further support to the hypothesis that specific subsets of GABAergic
interneurons are affected in schizophrenia in distributed brain regions, all with a common
connectivity.
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4.4 Critique of Work
Any time research is preformed utilizing humans, certain problems may arise. This
statement is applicable to both living human subjects and post-mortem tissue. Since
humans have many complex interactions with their environment and have intricate
genetic diversities, it is difficult to control for any study. However, attempts are made to
lessen the confounding effects of extraneous interactions in experiments dealing with
patients. This is mainly performed using statistical applications to normalize data and
remove confounding factors. Our study was designed to minimize differences by pairmatching based on age and PMI.

Nevertheless, factors beyond our control may

contribute to our findings. To combat this, we would need to perform an extensive chart
review on each patient to account for other medications, duration of treatments, other
disease or conditions, etc. Since this could not be done, we controlled in the most
applicable manner by pair-matching and performing more strict non-parametric tests to
explain our findings.

4.4.1 Post-Mortem Tissue
qRT-PCR studies elucidating GABA deficits in patients with schizophrenia were
performed using total RNA extracted from post-mortem tissue. Since it is virtually
impossible to study molecular mechanisms in living humans, post-mortem tissue analysis
becomes extremely important.

However, this type of analysis does not allow for

mechanistic studies or manipulations of the tissue. Additionally, issues with RNA quality
have been raised based on PMI, but our samples showed intact quality total RNA as
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shown by RIN >7.0. Nonetheless, this is the best way to study gene expression in
humans.

4.4.2 qRT-PCR Analysis
Our results were obtained using the technique of qRT-PCR. While the experiments were
all conducted in the same manner, the volume of experiments run precluded the use of
only one real-time PCR machine. Time and scheduling issues caused us to run our
experiments on three different Applied Biosystems thermalcyclers.

Ideally, these

experiments would be carried out on the same machine, but was impossible. Our data,
however, was consistent and validated on each machine used.

4.4.3 Evaluation of Medication Effects in Animal Models
Since none of the patients in this study were neuroleptic naïve, the effects of
antipsychotic on gene expression were evaluated using rodent models. The doses of
clozapine and haloperidol that used here were based on previous studies showing high
levels of D2 receptor occupancy (Bai et al., 2004). Nevertheless, one limitation is that
we used a 6 month exposure paradigm for haloperidol versus a 21 day exposure paradigm
for clozapine. Since the effects of these different treatments were not compared to each
other, but were compared to the levels in the patients, we do not consider this to be a
major shortcoming in our study.
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4.4.4 Animal Model of Schizophrenia
Schizophrenia is a purely human disease involving complex perceptional and cognitive
aspects. Reproducing this disease in an animal model is challenging, as many animal
models of schizophrenia exist. In the chronic intermittent exposure paradigm that we
used rats are sacrificed 3 days after the last PCP exposure. Thus, these animals are useful
to model the residual illness in the patients rather than an active psychotic episode, which
is modeled by acute PCP exposure. Furthermore, because we used a low dose of PCP, it
is unlikely that the animals were experiencing any withdrawal at the time they were
sacrificed. Ultimately, our model was shown to reproduce the GABAergic deficits seen
in patients and is, therefore, useful in examining the GABA dysfunction seen in
schizophrenia.

4.4.5 In Situ Hybridization Analysis
Analysis of in situ hybridization images was not performed blind to the experiment. This
creates an inherent bias and may influence the findings and the significance of the results.

4.5 Future Perspectives
It is clear that GABAergic interneurons in distributed brain regions show deficits in
markers related to signaling, such as GAD67 and GAT-1 (Benes and Berretta, 2001;
Lewis et al., 2005). However, further research must be performed in order to determine
the reason why certain subsets of GABAergic interneurons are preferentially affected
over others. Polymorphisms in the promoter for GAD67 have been identified in patients
with schizophrenia, some of which were shown to affect the rate of transcription (Straub
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et al., 2007).

Moreover, epigenetic mechanisms, such as increased levels of DNA

methyltransferase 1 (DNMT1), which correspond to decreased levels of GAD67 and
reelin, another marker of GABAergic cells, were found in specific cortical layers from
patients (Veldic et al., 2004; Ruzicka et al., 2007). Additionally, animal models of
methionine induced hypermethylation were found to affect the expression of GAD67 and
reelin, a developmental marker (Tremolizzo et al., 2002; Dong et al., 2005). More recent
epigenetic studies have implicated tri-methylation of histone H3-lysine 4 (H3K4me3) in
the activity of GABAergic gene promoters, such as GAD67, GAD65, somatostatin, and
reelin in patients (Huang and Akbarian, 2007; Huang et al., 2007). Epigenetic alterations
linked to reelin may lead to abnormal cellular migration, as seen by increased interstitial
white matter cells in the PFC (Akbarian et al., 1996a) and in the hippocampus (Eastwood
and Harrison, 2003, 2006).

These genetic and epigenetic differences in patients may confer a high degree of
sensitivity to GABAergic interneurons, making them more vulnerable to environmental
insults. However, these findings do not explain the mechanism behind dysfunction of
specific subsets of cells, placing importance on identification of new markers that can
distinguish among different subtypes of GABAergic interneurons, particularly those that
can predict a selective cellular dysfunction. Along these lines, it will be important to
measure the levels of different GABAA receptors in vivo in the patients by designing
specific radioligands for these receptors, whose binding could be detected using positron
emission tomography (PET). Regardless of the mechanism, it is clear deficits in
GABAergic interneurons contribute greatly to the pathophysiology of schizophrenia.

61

Patients could benefit greatly from treatment with selective GABA receptor agonists,
medications targeting specific modulators of GABA release, or treatment with
medications that treat epigenetic regulation in GABAergic interneurons.

4.6 Conclusion
Our study has shown that patients with schizophrenia have decreased expression of
markers of GABA neurotransmission in the lateral cerebellar hemispheres, regions linked
to cognition (Schmahmann and Sherman, 1998; Middleton and Strick, 2001; Ramnani,
2006; Thach, 2007). This supports the current hypothesis of GABAergic dysfunction in
other brain regions of patients. Furthermore, our results from chronic intermittent lowdose PCP administration in rats reproduced many of the GABA deficits seen in our
patient cohort. Furthermore, we localized deficits in one of the major GABA markers,
GAD67, to a specific subset of GABAergic interneurons in the cerebellar cortex, Golgi
cells. This is an exciting finding which shows GABA deficits in the cerebellum are
similar to those found in other brain regions, specifically those important in cognition.
These findings may ultimately contribute to better therapeutic interventions to ameliorate
the dysfunction experienced by patients with schizophrenia.
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Abbreviations Used
5-HT2A

Serotonin Receptor Subunit 2A

ANCOVA

Analysis of Covariance

BC

Basket Cell

BDNF

Brain Derived Neurotrophic Factor

CCTCC

Cortico-Cerebellar-Thalamic-Cortical Circuit

CF

Climbing Fibers

COMT

Catechol-o-methyl Transferase

DA

Dopamine

DAAO

D-Amino Acid Oxidase

DAB

Diaminobenzidine

DISC1

Disrupted in Schizophrenia 1

DNMT1

DNA Methyltransferase 1

GABA

γ-aminobutyric acid

GAD65

Glutamic Acid Decarboxylase 65kDa Isoform

GAD67

Glutamic Acid Decarboxylase 67kDa Isoform

GAP-43

Growth Associated Protein 43

GAT-1

Presynaptic GABA Reuptake Transporter

GCL

Granule Cell Layer

GL

Cerebellar Glomerulus

GluR6

Low Affinity Ionotropic Glutamate Receptor – Kainate GluR6 Subunit

GoC

Golgi Cell

GrC

Granule Cell
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H3K4me3

Histone H3-lysine 4 tri-methylation

IHC

Immunohistochemistry

KA2

High Affinity Ionotropic Glutamate Receptor – Kainate KA2 Subunit

LTP

Long Term Potentiation

MF

Mossy Fibers

MFC

Medial Frontal Cortex (Rat)

mGluR2

Metabotropic Glutamate Receptor 2

mGluR3

Metabotropic Glutamate Receptor 3

ML

Molecular Layer

MRS

Magnetic Resonance Spectroscopy

NAA

n-acetylaspartate

NAAG

n-acetylaspartylglutamate

NHS

Normal Horse Serum

NMDA

N-methyl-D-aspartate

nNOS

Neuronal Nitric Oxide Synthase

NO

Nitric Oxide

NR1

N-methyl-D-aspartate Receptor Subunit 1

NR2A-D

N-methyl-D-aspartate Receptor Subunit 2A-D

NRG1

Neuregulin 1

PC

Purkinje Cell

PCL

Purkinje Cell Layer

PCP

Phencyclidine

PF

Parallel Fibers
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PFC

Prefrontal Cortex (Human)

PMI

Post-Mortem Interval

qISH

Quantitative In Situ Hybridization

qRT-PCR

Quantitative Real Time Polymerase Chain Reaction

RIN

RNA Integrity Number

RSG4

Regulator of G-Protein Signaling 4

SC

Stellate Cell

SPET

Single Positron Emission Tomography

TBS

Tris Buffered Saline
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Appendix A.1

a

b

Supplementary Figure A.1.1. 10µm thick sections from rats treated with either a) saline or b) PCP.
Sections were labeled with S35-GAD67 riboprobe and counterstained with DAB following mGluR2
immunohistochemistry at 10X magnification. Decreases were seen in number of GAD67 expressing
Golgi cells in the granule cell layer and in GAD67 expression of Golgi cells in PCP rats. No other
changes were seen. Bar represents 50µm.
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Appendix A.2

Hybridization of Affymetrix HG-U133_2.0 Plus microarrays (Affymetrix; Santa Clara,
CA) from 14 patients with schizophrenia and 14 comparison subjects was performed at
the Translational Genomics Research Institute (T-GEN). Raw data was analyzed using
GeneSpring GX (Agilent Technologies; Santa Clara, CA). Data was normalized to the
median of all chips and clustered by condition (Supplemental Figure A.2.1). Filtering on
14 of 28 flags present and fold change of 1.2 produced a gene list of 1023 genes. Certain
genes from this list (BAX, MAP3K3, NTRK3, SP1,) were validated by qRT-PCR as
described in the methods section (Supplementary Figures A.2.9 – A.2.17). Additionally,
two genes related to GABA function (GABRB3 and NOS1) were identified and
examined by qRT-PCR (Figures 3.1 and 3.3).

The gene list created from GeneSpring GX was entered into GeneGo MetaCore™
(Encinitas, CA) and analyzed using standard algorithms. A network showing interactions
between selected genes from the gene list was created using expression data from qRTPCR analysis (Supplementary Figure A.2.2). Additionally, maps were created from the
gene list show the greatest number of hits in pathways associated with BAD
phosphorylation, CDC42 pathways, G-protein mediated regulation of p38 and JNK
signaling, JNK pathway, neurotrophin signaling, and p53-dependent apoptosis. These are
represented below (Supplementary Figures A.2.3 – A.2.8).
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Selected Condition Tree:
Colored by:
Gene List:

Condition Clustering with All Flags on Data Normalization
Schizophrenics vs. Controls (Default Interpretation)
all genes (54675)

Supplementary Figure A.2.1. GeneSpring condition clustering from 14 patients with schizophrenia
and 14 comparison subjects with data normalization to the median intensity of all chips. The patients
with schizophrenia cluster independently from the comparison subjects without any other
manipulations.
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Supplementary Figure A.2.2.
GeneGo MetaCore™ network showing interactions among genes
validated using qRT-PCR from GeneSpring GX gene list and selected GABA markers. These genes
include MAP3K3, TrkC, MBP, BAX, GAD67, GAD65, and GAT-1.
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Supplementary Figure A.2.3.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in BAD phosphorylation.

70

Supplementary Figure A.2.4.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in CDC42 in cellular processes.
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Supplementary Figure A.2.5.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in G-protein mediated regulation of p38 and JNK signaling.
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Supplementary Figure A.2.6.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in the JNK pathway.
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Supplementary Figure A.2.7.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in neurotrophin family signaling.
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Supplementary Figure A.2.8.
GeneGo MetaCore™ map showing interactions among genes from
GeneSpring GX gene list involved in p53-dependent apoptosis.

75

BAX Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.9. Analysis of BAX gene expression by SYBR® Green qRT-PCR. Data
is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test). **p<0.01, ***p<0.001.
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hBDNFcds Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.10.
Analysis of hBDNFcds gene expression by SYBR® Green qRTPCR. Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test),
and pair matched (analysis by Wilcoxon Signed Rank test).
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MAP3K3 Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.11. Analysis of MAP3K3 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers (analysis by t test) and pair matched (analysis by Wilcoxon
Signed Rank test). **p<0.01, ***p<0.001.
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MBP Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.12.
Analysis of MBP gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test). *p<0.05.
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NF3 Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.13.
Analysis of NF-3 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test).
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TrkB Graphs - Patients with Schizophrenia

NTRK2 with Outliers

NTRK2 without Outliers
5

Relative mRNA Levels

Relative mRNA Levels

6
5
4
3
2
1
0

4
3
2
1
0

Schizophrenics

Controls

Schizophrenics

p = 0.6832

Controls

p = 0.1141

NTRK2
Relative mRNA Levels

6
5
4
3
2
1
0
Schizophrenics

Controls

p = 0.5879

Supplementary Figure A.2.14.
Analysis of TrkB gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test).
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TrkC Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.15.
Analysis of TrkC gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test). **p<0.01.
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panTrkB Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.16. Analysis of panTrkB gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test).
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SP1 Graphs - Patients with Schizophrenia
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Supplementary Figure A.2.17. Analysis of SP1 gene expression by SYBR® Green qRT-PCR. Data
is represented as unpaired with outliers and unpaired without outliers (analysis by t test), and pair
matched (analysis by Wilcoxon Signed Rank test). *p<0.05.
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Appendix A.3

This appendix consists of unpaired qRT-PCR graphs from GABAergic markers, NMDA
receptor subunits, and cerebellar neuromodulators of GABAergic release. All of these
analyses were performed using t tests and show the same results as the non-parametric
pair-matched data shown in the text (Figures 3.1 – 3.3) with the exception of GABAA-β3,
which is significantly increased using this analysis. Data is shown as average of gene
expression levels of the gene of interest in patients with schizophrenia versus comparison
subjects. Analyses with statistical outliers (+2 SD) and without statistical outliers are
both shown.
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Supplementary Figure A.3.1.
Analysis of GABAA-α6 gene expression by TaqMan® qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
**p<0.01.
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GABAA-β
β 3 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.2.
Analysis of GABAA-β3 gene expression by SYBR® Green qRTPCR. Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
*p<0.05.
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GABAA-δ
δ Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.3.
Analysis of GABAA-δ gene expression by TaqMan® qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
**p<0.01, ***p<0.001.
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GAD67 vs. β -actin Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.4.
Analysis of GAD67 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test). *p<0.05.
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GAD65 vs. β -actin Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.5.
Analysis of GAD65 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test). *p<0.05.
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GAT-1 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.6.
Analysis of GAT-1 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
**p<0.01, ***p<0.001.
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Parvalbumin Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.7.
Analysis of Parvalbumin gene expression by SYBR® Green qRTPCR. Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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NR1 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.8. Analysis of NR1 gene expression by SYBR® Green qRT-PCR. Data
is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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NR2A Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.9.
Analysis of NR2A gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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NR2B Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.10.
Analysis of NR2B gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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NR2C Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.11.
Analysis of NR2C gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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NR2D Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.12.
Analysis of NR2D gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test). *p<0.05.
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GluR6 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.13.
Analysis of GluR6 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
**p<0.01, ***p<0.001.
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KA2 Graphs - Patients withSchizophrenia
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Supplementary Figure A.3.14.
Analysis of KA2 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
***p<0.001.
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mGluR2 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.15. Analysis of mGluR2 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
*p<0.05.
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mGluR3 Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.16. Analysis of mGluR3 gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test).
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nNOS Graphs - Patients with Schizophrenia
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Supplementary Figure A.3.17.
Analysis of nNOS gene expression by SYBR® Green qRT-PCR.
Data is represented as unpaired with outliers and unpaired without outliers (analysis by t test). *p<0.05,
***p<0.001.
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Appendix A.4

This appendix contains qRT-PCR analysis of GAD67, GAD65, and GAT-1 normalized to
cyclophilin from patients with schizophrenia versus comparison subjects. Data was
analyzed using both unpaired (analyzed by t-tests) and pair-matched (analyzed by nonparametric Wilcoxson Signed Rank test). Data derived from normalization to cyclophilin
was similar to data derived from normalization to β-actin.
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Supplementary Figure A.4.1.
Analysis of GAD67 gene expression by SYBR® Green qRT-PCR
normalized to cyclophilin. Data is represented as unpaired with outliers and unpaired without outliers
(analysis by t test). ***p<0.001.
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GAD65 vs. Cyclophilin Graphs - Patients with
Schizophrenia
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Supplementary Figure A.4.2.
Analysis of GAD65 gene expression by SYBR® Green qRT-PCR
normalized to cyclophilin. Data is represented as unpaired with outliers and unpaired without outliers
(analysis by t test). **p<0.01.
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GAT-1 vs. Cyclophilin Graphs - Patients with
Schizophrenia
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Supplementary Figure A.4.3.
Analysis of GAT-1 gene expression by SYBR® Green qRT-PCR
normalized to cyclophilin. Data is represented as unpaired with outliers and unpaired without outliers
(analysis by t test). ***p<0.001.
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Appendix A.5

Data in this appendix is a comparison of gene expression data from patients who were
receiving typical antipsychotics at the time of death versus those who were receiving
atypical antipsychotics (Table 2.1). Significant changes were seen in the expression of
GAD67 (Supplementary Figure A.5.4), NR2A (Supplementary Figure A.5.9), and SP1
(Supplementary Figure A.5.23).

Data were analyzed using non-parametric Mann-

Whitney Rank Sum test to account for non-parametric distribution of the data.
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Supplementary Figure A.5.1.
Medication subtype analysis of GABAA-α6 gene expression by
TaqMan® qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.2.
Medication subtype analysis of GABAA-β3 gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.3.
Medication subtype analysis of GABAA-δ gene expression by
TaqMan® qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.4.
Medication subtype analysis of GAD67 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test). *p<0.05.
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Supplementary Figure A.5.5.
Medication subtype analysis of GAD65 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.6.
Medication subtype analysis of GAT-1 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.7.
Medication subtype analysis of Parvalbumin gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.8.
Medication subtype analysis of NR1 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).

115

Relative mRNA Levels

NR2A - Medication Effects
9
8
7
6
5
4
3
2
1
0

*

Typicals

Atypicals

p = 0.0140

Supplementary Figure A.5.9.
Medication subtype analysis of NR2A gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test). *p<0.05.
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Supplementary Figure A.5.10.
Medication subtype analysis of NR2B gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.11.
Medication subtype analysis of NR2C gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.12.
Medication subtype analysis of NR2D gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.13.
Medication subtype analysis of GluR6 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.14.
Medication subtype analysis of KA2 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).

121

Relative mRNA Levels

mGluR2 - Medication Effects
10
9
8
7
6
5
4
3
2
1
0
Typicals

Atypicals

p = 0.8357

Supplementary Figure A.5.15.
Medication subtype analysis of mGluR2 gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.16.
Medication subtype analysis of mGluR3 gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.17.
Medication subtype analysis of nNOS gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.18.
Medication subtype analysis of BAX gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.19.
Medication subtype analysis of hBDNFcds gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.20.
Medication subtype analysis of MAP3K3 gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.21.
Medication subtype analysis of MBP gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.22.
Medication subtype analysis of NF3 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).

129

SP1 - Medication Effects
Relative mRNA Levels

4
3
2

*

1
0
Typicals

Atypicals

p = 0.0221

Supplementary Figure A.5.23.
Medication subtype analysis of SP1 gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test). *p<0.05.
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Supplementary Figure A.5.24.
Medication subtype analysis of TrkB gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.25.
Medication subtype analysis of panTrkB gene expression by
SYBR® Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of
death versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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Supplementary Figure A.5.26.
Medication subtype analysis of TrkC gene expression by SYBR®
Green qRT-PCR. Data is represented as patients receiving typical antipsychotics at the time of death
versus those receiving atypical antipsychotics (analysis by Mann-Whitney Rank Sum test).
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